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         CK2 is a serine/threonine kinase, with 2 catalytic subunits (α and α’) and 2 
regulatory subunits (β).  CK2 phosphorylates and activates substrates in several pathways 
implicated in cancer progression such as PI3K/AKT, NF-κB, and JAK/STAT pathways; 
thus increased CK2 activity can promote cancer growth. Abnormally high levels of CK2 
expression at the DNA, RNA, and protein levels have been found in many studies of 
several different cancer types. Inhibition of CK2 using antisense oligonucleotides (ASOs) 
designed to target various CK2 subunits and thus inhibit phosphorylation of CK2 
substrates decreases signaling through the various pathways implicated in cancer 
progression. As such, treatment with CK2 ASOs leads to decreased cancer cell 
proliferation, cell-cycle arrest, as well as decreased cell viability. CK2 inhibition using 
specific inhibitors such as TBB, CIGB-300, CX-4945, quinalizarin, emodin has achieved 
similar efficacy in inhibiting CK2, displaying reduction of cell viability, decreased cell 
proliferation, induction of apoptosis, and inhibition of PI3K/AKT, NF-kB, and 
JAK/STAT signaling pathways in several cancer cell models. Inhibition of the 
PI3K/AKT and NF-kB pathways was demonstrated by presence of decreased 
phosphorylated active forms of CK2 substrates, as well as reduced amounts of other 




shown promising results, as mice inoculated with solid tumors from a wide range of 
cancer types have responded promisingly to treatment with CK2 inhibitors. Mice treated 
with CK2 inhibitors in these studies show improved survival, decreased cell proliferation, 
and reduced tumor volume in comparison to vehicle-treated control mice. In addition, 
these mice have lower quantities of phosphorylated CK2 substrates, including those in 
the PI3K/AKT, and NF-kB cascades. Further, CK2 inhibition has proven to be 
efficacious when used in combination with other chemotherapeutics, with combination 
treatment often showing greater efficacy when compared to either monotherapy (CK2 
inhibition alone or chemotherapy alone) in both cell models and in xenograft mice. In 
cells models, these combination therapies have shown significantly greater reduction in 
cell viability and proliferation, and induced apoptosis to a greater extent that either CK2 
inhibition or chemotherapy administered alone, with these trends observed in cell lines 
that are typically resistant to the chemotherapeutic being used (e.g. cisplatin, or 
paclitaxel). Similarly, xenograft mice treated with combination dosing regimens of CK2 
inhibitor and a traditional chemotherapeutic have also shown greater anti-cancer effects 
when compared to mice treated with either therapy alone; combination treatment mice 
often have decreased tumor volume, less tumor growth, and a significant increase in 
survival, as well as apparent inhibition of CK2-dependent phosphorylation cascades. CK2 
inhibitors CX-4945 and CIGB-300 have also been used in human patient clinical trials, 
with CIGB-300 showing tolerability and efficacy when used for treatment of invasive 
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 Cancer As a Set of Diseases With Variable Targets and Therapeutic Approaches  
         In the United States alone, there are 1.6 million new cases of cancer diagnosed 
each year (Tarver and Haggstrom 2019). Cancer is a unique set of diseases that 
effectively disable the body’s mechanisms to regulate cell-growth, through both protein 
pathways and simple contact inhibition (Wu et al. 2019). Because this group of diseases 
is extremely variable, and the tissues that they occur in are limitless, the prospect of a 
blanket cure is all but eliminated (Wu et al. 2019). Protein kinases are a set of enzymes 
that catalyze the phosphorylation of other proteins, which regulates a wide range of 
cellular processes (Cicenas et al. 2018). These processes range from cell cycle 
progression, apoptosis, motility of cellular components, cell differentiation, cell 
proliferation, and many others (Cicenas et al. 2018). The deregulation of kinases often 
leads to the survival and metastasis of cancer cells (Cicenas et al. 2018). One of the most 
perilous mechanisms by which cancer can develop and grow is through mutations to 
kinases that render them constitutively active (Cicenas et al. 2018). This creates great 
dysregulation within the cell and can lead to cancerous growth (Cicenas et al. 2018). 
Because of their cancer-promoting abilities, kinases such as ERK, AKT kinases, JAK 
kinases, CK2 kinases and others have been pharmacological drug targets for novel 





One cascade that has been shown to have substantial cancer causing potential is 
the PI3K-AKT cascade (Trembley et al. 2017). AKT kinases act as signaling molecules 
for differentiation of cells and cell growth (Revathidevi and Munirajan 2019). AKT has 
been reported to have a ~40% activity increase in many common cancers such as 
prostate, gastric, and epithelial cancers (Revathidevi and Munirajan 2019).  Aberrant 
activity of the AKT cascade oncoproteins and tumor suppressor proteins lead to 
inhibition of apoptosis, cytoskeletal rearrangement and cell proliferation (Revathidevi 
and Munirajan 2019). GTP-bound Ras initiates PI3K/AKT signaling by activating PI3K 
(Revathidevi and Munirajan 2019). Active PI3Kconverts molecule PIP2 to PIP3 which 
leads to recruitment of AKT to the plasma membrane to bind PDK1 which subsequently 
phosphorylates AKT, which activates mTOR. mTOR activates a broad set of targets that 
encompass angiogenic factors, hypoxic factors, transcriptional factors, and translation-
initiation factors leading to increased cell survival and cell growth (Revathidevi and 
Munirajan 2019). Therefore an overactive AKT/PI3K cascade results in inhibition of 
apoptosis and significant increase in cell proliferation. Independent of the AKT/PI3K 
cascade, AKT isoforms are considered oncogenes as they are found overexpressed in 
many human cancers, leading to further development of cancer (Revathidevi and 





Figure 1. Schematic of the AKT/PI3K Cascade and Downstream Events. Certain 
growth stimuli activate PI3K, which leads to downstream events culminating in AKT 
activation and subsequent pro-cancer effects (Adapted from Revathidevi et al, 2019).  
The JAK-STAT pathway is another kinase signaling cascade that has proven to 
have tumorigenic potential in several cancers due to its ability to contribute proliferation, 
cell survival, cancer cell invasion, as well as cancer cell immunity (Pencik et al. 2016). 
Signaling in the JAK-STAT pathway leads to eventual autoactivation of JAK kinases, 
which leads to a cascade of events that culminate in receptor dimerization, cross-
phosphorylation of JAK kinases, and the subsequent movement of JAK kinases to allow 
for activity of downstream kinases in the pathway (Pencik et al. 2016). The activity of 




after being phosphorylated, and moving into the nucleus with cooperation of GTPase 
activity (Pencik et al. 2016). JAK kinases can be activated in a transient fashion by 
cytokines (including IL-6, type I and II IFN’s) and growth factors (i.e. growth hormone) 
in normal functioning cells, but mutations can cause JAK kinases to become 
constitutively active (Zheng et al. 2013). These constitutively activating mutations 
contribute to a majority of the pro-cancerous effects that the JAK/STAT signaling 
pathway has on cell proliferation, cell survival, and cancer cell invasion (Zheng et al. 
2013; Johnson, O’Keefe, and Grandis 2018; Pencik et al. 2016). In addition, within the 
JAK kinase family, JAK2 has been found to be mutated in a significant proportion of 
neoplasms, including prostate cancer, making JAK2 a potentially beneficial target for 
treatment of these diseases (Pencik et al. 2016).  
Another significant cancer-causing pathway involves the well-studied 
transcriptional factor NF-κB. NF-κB has been found particularly relevant in GI, liver, 
pancreatic, and lung cancers which is likely to do with the fact that these cancers are 
associated with significant inflammation (Taniguchi and Karin 2018). NF-κB is a family 
of five individual DNA-binding proteins (also referred to as transcription factors) which 
can form different hetero and homodimers (Taniguchi and Karin 2018). The proteins in 
the NF-κB family encompass many functions that serve to regulate immune response 
including inflammation, inhibition of apoptosis, upregulation of cell proliferation, as well 
as promotion of metastasis and allowing for increased migration and invasion of cells 
(Taniguchi and Karin 2018). The significant transcription factors that form the 




containing trasnactivation domains that have been shown to give transcriptional activity 
to dimers they are part of (Christian, Smith, and Carmody 2016). In resting cells, NF-κB 
is kept in the cytoplasm through direct binding with a member of IkB inhibitor protein 
family. The most significant way that NF-κB is kept at a basal activity level is via a 
negative feedback loop that necessitates IkB-α expression induced by NF-κB (Christian, 
Smith, and Carmody 2016). NF-κB has both a classical pathway of activation and 
alternative activation pathways. The classical pathway is the most studied NF-κB 
activation pathway, which involves activation of IKK (IkB kinase complex) that 
phosphorylates NF-κB-bound IkB (inhibitor of NF-κB) which allows for IkB to be 
targeted for degradation, liberating dimers containing p65, p50, cREL to thereby enter the 
nucleus and alter transcription of target genes (Karin and Greten 2005). The other 
pathway of activation involves a kinase upstream of NF-κB called NF-κB-inducing 
kinase (NIK) which is activated upon stimulation with certain TNF cytokines. NIK 
activates homodimers of IKK α and this leads to eventual activation NF-κB (Karin and 
Greten 2005; Taniguchi and Karin 2018). NF-κB can  also be activated by IL-33, which 





Figure 2. Aberrant NF-ΚB Activity is Pro-Cancerous due to Inflammation and Cell 
Proliferation Functions (Adapted from Christian et al, 2016)  
CK2 Biological Significance and Role in Cancer  
CK2 is a family of serine/threonine kinases (CK2 α and CK2α’) that can each 
work as a monomeric kinase, and also as part of a tetrameric complex composed of two 
catalytic subunits (α and α’) that are connected via two regulatory (β) subunits (Trembley 
et al. 2017). CK2 protein levels have been shown to be elevated in all cancers for which 
CK2 levels have been quantified (Gray et al. 2014). CK2 has shown the ability to activate 
other kinases that are implicated in several tumorigenic pathways, which  can have 
negative implications on the clinical prognosis of patients given the growing amount of 
evidence suggesting that CK2 is constitutively active in many cancers (Mandato et al. 




holoenzyme, the level of protein expression of the regulatory subunits does not affect the 
level of expression of the catalytic subunits, and evidence is accumulating that the 
subunits of CK2 are asymmetrically distributed and function independently of one 
another in many respects (Guerra 2006; C. W. Yde et al. 2008). This was shown via 
HeLA cell treatment with CK2B-antisense oligonucleotides (ASO). ASOs are 
oligonucleotides that are designed to bind a specific sequence of mRNA and prevent 
synthesis of the protein that the mRNA encodes (Seeber et al. 2005). Treatment of HeLA 
cells with CK2B-ASO depleted cells of the CK2β subunit at the protein level, and despite 
this depletion the protein levels of the catalytic CK2 subunits (α and α’) remained at a 
level similar to control samples (Guerra 2006). By contrast, it has also been shown that 
inhibition of CK2α unit using siRNA, has shown decreased protein levels of CK2β in 
MEF’s, which is a previously shown effect in both MCF-7 cells as well as CK2α 
knockout mice (Zheng et al, 2013; Dominguez et al 2005, Seldin et al 2005).. . The Ck2β 
subunit has no catalytic activity, and both CK2α and CK2α’contribute to the activity of 
the CK2 holoenzyme (Guerra 2006). This is demonstrated by the greatest reduction in 
CK2 kinase activity in HeLA cells via treatment of cells with a CK2a/a’-ASO designed to 





Figure 3. CK2 Signaling Pathway and Implicated Downstream Pathways  (Krentz 
Gober 2017) 
In terms of cellular function, CK2 protein activity has been previously implicated 
in  cell proliferation, suppression of apoptosis, potentiating cell cycle progression, and 
cell growth (Trembley et al. 2017; Guerra 2006; C. W. Yde et al. 2008). CK2 cell 
signaling is also crucial for cell survival, specifically cell survival of cancer cells, by 
allowing them to evade apoptosis and proliferate, furthering cancer progression (Huamin 
Wang et al. 2001; Trembley et al. 2017). Di Maira et al., investigated the effect of CK2 in 
suppressing apoptosis through treatment of Jurkat cells with selective CK2 inhibitors 




a]quinazoline-7-acetic acid (IQA), with both CK2 inhibitors inducing cell death by 
apoptosis (Di Maira et al. 2005). The ability of CK2 to suppress apoptosis is well-
documented, as treatment of several cell lines both cancerous (HCT116, HeLa, 
HCC1937) and human primary cells (Jurkat) with an ASO targeting one CK2 catalytic 
subunit or both (α and/or α’), significantly enhances the effects of various well known 
apoptosis-inducing agents, when compared to controls or apoptosis-inducing agent alone 
(Seeber et al. 2005; Guerra 2006). CK2 also has a role as a critical regulator and 
potentiator of cell cycle progression, with various points of regulation and potentiation 
both within the cell cycle and prior to entry into mitosis (Pepperkok et al. 1994; C. W. 
Yde et al. 2008; Homma et al. 2005). Stimulation of cell proliferation appears to be 
dependent on a certain level of CK2 in both cytoplasm and nucleus, shown by reduction 
of cell proliferation/stimulation when adding either polyclonal or monoclonal antibodies 
to CK2β (Pepperkok et al. 1994). Furthermore, use of the anti-CK2β antibodies inhibited 
cell proliferation during the G0/G1 phase transition, early G1 phase, and G1/S phase 
transition, but there was no observed inhibition after treatment with CK2β antibodies 
during S phase of the cell cycle (Pepperkok et al. 1994). The effects of cell treatment with 
CK2β antibodies was abolished by adding purified CK2, showing the inhibition of cell 
growth to be reversible (Pepperkok et al. 1994). The CK2β subunit has also been shown 
to be critical in the G2/M phase transition through interaction with several well-described 
kinases involved in cell-cycle progression (C. W. Yde et al. 2008). Depletion of CK2β 
using siRNA, led to stabilization of Wee1, a kinase that inhibits cell cycle progression 




for entry into mitosis) by phosphorylating it on Tyr15, which effectively leads to delayed 
cell-cycle progression (C. W. Yde et al. 2008). Evidence for this resides in cells 
transfected with CK2β siRNA having a 40% decrease in CDK1 activity when compared 
to cells transfected with scramble siRNA, also known as a mock condition (C. W. Yde et 
al. 2008). Phosphorylation activity levels of CK2 have been shown to increase in a time-
dependent manner following stimulation with fetal bovine serum (promotes cell growth), 
with CK2 activation 2.5 fold higher 3 hours post-stimulation, returning to basal levels 
approximately 9 hours later (Homma and Homma 2008).  However, observation of this 
increase in CK2 phosphorylation activity was dependent on the synthetic substrate used, 
as it was not observed in a substrates with serine residues, but not in phosphorylation 
substrates that were  serine-deficient synthetic peptide substrate (Homma and Homma 
2008). CK2 has also been shown to phosphorylate eIF5 at sites Ser389 and 390, Thr207 
and 208, additionally, specific subunits of CK2 have also been shown to have interactions 
with eIF5 (Homma et al. 2005; Homma and Homma 2008). This is significant because 
the phosphorylation of eIF5 has been shown to be important to the formation of a mature 
translation-initiation complex, the joining of the 40S and 60S ribosomal subunits 
(Homma and Homma 2008). eIF5 has been shown to associate with CK2α subunit in G1 
phase of the cell cycle, and CK2β has been shown to be necessary for eIF5 
phosphorylation by CK2 (Homma and Homma 2008). Evidence for the requirement of 
CK2β in eIF5 phosphorylation by CK2 was generated via in vitro studies where CK2α 
and recombinant-eIF5 were incubated together, with increasing amounts of CK2β added, 




and Homma 2008). Further evidence for the required CK2 phosphorylation of eIF5 is 
shown in vitro in COS-7 cells with overexpressed mutant eIF5, lacking aforementioned 
CK2 phosphorylation sites, subsequently showing dominant-negative effects on eIF5 
phosphorylation (Homma and Homma 2008). In addition, CK2 selective inhibition with 
either apigenin (pharmacological inhibitor of CK2), or RNAi showed decreased eIF5 
phosphorylation (Homma and Homma 2008). CK2 phosphorylation of eIF5 to ensure 
proper maturation of the translation-initiation complex also stimulates translational 
regulators such as Cyclin B1 which in turn may promote synthesis of proteins needed for 
entry into mitosis (Homma and Homma 2008).  
CK2 has been shown to interact with several other kinases and transcription 
factors that are in commonly implicated tumorigenic pathways that have been major drug 
targets for new targeted therapies. These include kinases such as AKT  and JAK/STAT3. 
CK2 has been shown to have strong effects in positively regulating AKT kinase, shown 
by both Di Maira et al and Guerra et al, by two distinct mechanisms of direct 
phosphorylation and protein-protein interaction, each resulting in significant upregulation 
(Di Maira et al. 2005; Guerra 2006). The first of two mechanisms by which CK2 
upregulates AKT involves direct CK2-phosphorylation of Ser129 of AKT (specific serine 
identified via SDS-PAGE and verified via MALDI mass spectrometry), with this 
phosphorylation shown to “hyperactivate” activated-AKT by approximately 2 fold (Di 
Maira et al. 2005). This hyperactivation of AKT was deemed to be due to CK2-
phosphorylation by experiments involving incubation of AKT, protein substrates of AKT, 




CK2-specific inhibitor TBB (Di Maira et al. 2005). The phosphorylation by CK2 at 
Ser129 of AKT was also demonstrated to occur in vitro in both Jurkat and HEK293T 
cells using phospho-specific antibodies that correspond to AKT amino acid residues 121-
140 (Di Maira et al. 2005). The second mechanism by which CK2 upregulates AKT is 
via a direct protein-protein interaction with AKT, shown through co-precipitation of AKT 
via immunoprecipitation methods using both polyclonal anti-CK2α and anti-CK2β 
antibodies, with corresponding analysis done using SDS-PAGE and western blot (Guerra 
2006). This was subsequently confirmed via immunoprecipitation using an anti-AKT 
polyclonal antibody that gave direct evidence of an AKT-CK2 complex via SDS-PAGE 
and Western blot analysis (Guerra 2006). The direct interaction between CK2 and AKT 
has been deemed significant because of the increased activity shown in AKT while 
interacting with CK2. AKT demonstrates an increased ability to phosphorylate histone 
2B, a substrate of AKT regularly assayed when assessing AKT kinase activity, with AKT 
phosphorylation of histone 2B determined to be approximately 4-fold higher (Guerra 
2006). Conversely, it was also shown that use of CK2-specific inhibitors TBB and IQA 
leads to decreased phosphorylation level of well-known AKT-substrates GSK3b Ser9, 
FKHR Ser256, and AFXSer193 (Di Maira et al. 2005). It was also demonstrated through 
use of RNAi in LNCaP cells that reduction of mRNA and protein expression specifically 
of CK2α (catalytic subunit) leads to reduction of AKT phosphorylation of the 
aforementioned well-known AKT substrates (Di Maira et al. 2005). In addition, there 
also exists a mechanism by which CK2 can activate the aforementioned potent 




suppressor, acts as a regulator of JAK-STAT pathway, and PML is a substrate of CK2 
(Zheng et al. 2013). Silencing of CK2α and/or CK2β using siRNA in MEFs (mouse 
embryonic fibroblasts) was shown to lead to reduced STAT-3 activation, measured by a 
reduction in total phosphorylated STAT3 (Phospho-STAT3 is the activated form), which 
notably included a significant reduction of Oncostatin M-induced (OSM-induced) 
STAT3 activation (Zheng et al. 2013). OSM is a cytokine with potent JAK-STAT 
phosphorylation-activation capability (Zheng et al. 2013).  Use of selective inhibitor TBB 
for 30 minutes pre-treatment of MEF cells also showed reduced OSM-tyrosine STAT3 
phosphorylation in a dose-dependent fashion (Zheng et al. 2013). There is also evidence 
to suggest that activation of JAK1 and JAK2 (receptor associated tyrosine kinases) by 
OSM is dependent on CK2, proven by lower levels of JAK1 and 2 phosphorylation after 
treatment with both CK2 siRNA’s and also preincubation with TBB and emodin (another 
selective inhibitor of CK2) (Zheng et al. 2013). There is also evidence to indicate that in 
HEL (a human erythroleukemia cell line) cells CK2 is required for JAK-STAT signaling, 
best supported by the inhibition of JAK-STAT signaling when HEL cells are treated with 
TBB (Zheng et al. 2013). CK2 has also been implicated in being a key regulator of the 
NF-κB pathway. In two cell lines with elevated NF-ΚB activation, CK2α and CK2β 
subunits were knocked down individually, which led to a subsequent increase in IkBA 
kinase (known inhibitor of NF-ΚB), indicative of less NF-ΚB activation (Brown et al. 
2010). It was also observed that knockdown of CK2β in HSNCC cell lines leads to 
significantly lower constitutive NF-ΚB p65 binding activity, and CK2α knockdown leads 




domain, this is effectively negative regulation (Brown et al. 2010). A decrease in NF-κB 
activation was also shown in multiple myeloma cell lines when cells were treated with 
CK2 inhibitors Silmitasertib (CX-4945) and K27 (Manni et al. 2013). When Ser529 of 
p65 (subunit of NF-ΚB) was upregulated by a bortezomib-induced mechanism, addition 
of CK2 inhibitors led to a significant downregulation of Ser529 of p65 in both U-266 
cells as well as Mantle cell lymphoma cells (Manni et al. 2013). This further reinforces 
the notion reviewed by Christian et al, that Ser529 of p65 is phosphorylated by CK2 after 
Il-1β or TNFα stimulation, which leads to p65 having gene-specific increased 
transactivation potential (Bird et al. 1997; D. Wang and Baldwin 1998; D. Wang et al. 
2000; Christian, Smith, and Carmody 2016). A physical interaction between endogenous 
CK2α and subunit p105 of NK-κB has also been discovered in multiple myeloma cells 
(Piazza, Manni, and Semenzato 2013). It was also shown that knockdown of CK2α 
subunit in HNSCC cell lines lead to decreased expression of NF-κB target genes that are 
associated with cell cycle progression survival and cell survival (Brown et al. 2010). This 
effect has been similarly shown in multiple myeloma cells through use of CK2 inhibitor 
CX-4945 suppressing expression of target gene of NF-κB (Manni et al. 2013). In human 
prostate cancer it has been shown that nuclear CK2a and NF-κB p65 proteins are 
significantly elevated in prostate cancer samples when compared to benign prostatic 
hyperplasia, which suggests the possibility that CK2 has a role in the degree of 





Figure 4. CK2 Effects on Cell proliferation and Survival This figure shows the role 
CK2 plays in many cellular processes as well as the wide range of pathways in which 
CK2 phosphorylation can promote cell proliferation, evasion of growth suppressors, cell 
death resistance, and the activation of invasion and metastasis mechanisms in cancer. 
Among the more significant events triggered by CK2 phosphorylation (Figure taken from 
Mandato et al. 2016) 
 
CK2 Transcript Expression in Cancer 
While elevated CK2 kinase activity has long been investigated and linked to other 
pro-cancerous kinase pathways, the transcript expression of the various CK2 subunits has 
also shown significant aberration in cancer, leading to further investigation into the 
viability of creating CK2 therapeutics at the genetic level. The three CK2 genes that have 
been researched in the context of genetic expression in various cancers are CK2α, CK2 
α’, CK2β, and also a pseudogene, CK2αP (Ortega, Seidner, and Dominguez 2014; Chua, 




transcript expression in several cancers (Ortega, Seidner, and Dominguez 2014; Chua, 
Lee, and Dominguez 2017). When specifically comparing cancerous tissue to adjacent 
normal tissue, expression of the various CK2 transcripts has been found to be either 
significantly upregulated or downregulated by at least 1.5 fold (Ortega, Seidner, and 
Dominguez 2014; Chua, Lee, and Dominguez 2017). Although the function of each CK2 
protein is known, the mechanism behind the differential expression of CK2 transcripts in 
various cancer types has not been elucidated. 
CK2α transcript expression has been found to be significantly upregulated in a 
wide range of cancers (Ortega, Seidner, and Dominguez 2014; Chua, Lee, and 
Dominguez 2017). These cancers include head and neck cancers, such as anaplastic 
oligoastrocytoma, and cervical cancer (Chua, Lee, and Dominguez 2017). There are also 
multiple GI cancers such as gastric intestinal type adenocarcinoma and colon adenoma 
that show significant overexpression of CK2α transcript (Chua, Lee, and Dominguez 
2017). The overexpression of CK2α is not limited to a particular sex as both male and 
female sex organ cancers exhibit overexpression of CK2α such as prostate carcinoma and 
ovarian serous adenocarcinoma. Several lung cancers show overexpression of CK2α such 
as squamous cell carcinoma of the lung, LCLC, and SCLC, among others (Ortega, 
Seidner, and Dominguez 2014). CK2α expression is found to be downregulated in several 
cancers as well; For example in Barrett’s Esophagus, follicular lymphoma, thyroid gland 
carcinoma and testicular seminoma, among others (Chua, Lee, and Dominguez 2017). 
For some cancers such as various breast carcinomas, pancreatic ductal adenocarcinoma, 




CK2α transcript expression is upregulated or downregulated as separate studies have 
suggested upregulation or downregulation (Ortega, Seidner, and Dominguez 2014). 
Further investigation is necessary to determine if there are other mitigating factors that 
influence the variability in over/under expression of CK2α transcripts in certain cancer 
subtypes.  
Table 1. Cancer Dependent Changes in CK2α Transcript Expression 






1.611 1.96x10-10 Chen Gastric 
Barrett’s Esophagus -2.356 5.27x10-10 Kim Esophagus  
Colon Adenoma 2.4 2.32x10-5 Skrzypczak 




1.666 0.008 French Brain 
Prostate Carcinoma 1.9 1.61x10-12 Lapointe 
Ovarian Serous 
Adenocarcinoma 
2.3 4.22x10-11 Yoshihara 
Squamous Cell 
Carcinoma of Lung 
18.9 1.5x10-7 Bhattacharjee 
LCLC 2.5 2.4x10-9 Hou 
SCLC 6 4.3x10-4 Bhattarcharjee 
Follicular Lymphoma -1.421 3.21x10-7 Compagno 
Lymphoma 





Testicular Seminoma -1.645 0.003 Sperger Others 
 (Table adapted from Chua, Lee and Dominguez, 2017) 
CK2α’ has cancer-dependent aberrant transcript expression as well (Ortega, 
Seidner, and Dominguez 2014; Chua, Lee, and Dominguez 2017). CK2α’ transcript 
expression is found to be upregulated in several cancers. These cancer types include 
bladder carcinoma, several oral carcinomas (tongue, and floor of the mouth), AML, CLL, 
cervical cancer, as well as others (Ortega, Seidner, and Dominguez 2014; Chua, Lee, and 
Dominguez 2017). In many sex organ cancers, transcript expression of CK2α’ is found to 
be downregulated, such as in seminoma and testicular teratoma (Chua, Lee, and 
Dominguez 2017). CK2α’ expression is also downregulated in fibrosarcoma,follicular 
lymphoma, and diffuse gastric adenocarcinoma (Chua, Lee, and Dominguez 2017). There 
is also disagreement on whether CK2α’ transcript expression is upregulated or 
downregulated in certain types of cancer, such as in melanoma, where datasets from 
different studies show aberrant expression with differing trends (Chua, Lee, and 
Dominguez 2017).  
Table 2. Cancer Dependent Changes in CK2α’ Transcript Expression 






1.775 4.17x10-6 Dyrskjot Bladder 3 




Floor of the Mouth 
Carcinoma 
1.99 0.011 Pyeon Multi-Cancer 
AML 2.030 1.47x10-7 Andersson 
Leukemia 
Seminoma  -8.257 8.56x10-11 Korkola Seminoma 
Testicular Teratoma -4.093 0.006 Skotheim Testis 
Fibrosarcoma -1.464 0.009 Detwiller Sarcoma 
Follicular 
Lymphoma 
-2.263 8.51x10-4 Storz Lymphoma 
Diffuse Gastric 
Adenocarcinoma 
-1.549 2.95x10-4 Cho Gastric  
 (Table adapted from Chua, Lee and Dominguez, 2017) 
Transcript expression of CK2β also has been documented to be irregularly 
expressed in cancerous tissue when compared to normal tissue (Ortega, Seidner, and 
Dominguez 2014; Chua, Lee, and Dominguez 2017). In many cancers, expression of 
CK2β transcript is found to be upregulated such as in astrocytoma, cervical cancer, 
gastric intestinal type adenocarcinoma, floor of the mouth carcinoma, clear cell renal cell 
carcinoma, colon carcinoma, and several types of breast cancer (Chua, Lee, and 
Dominguez 2017). CK2β transcript expression is downregulated in some cancer types as 
well, such as seminoma, testicular teratoma, teratoma (not otherwise specified), 
dedifferentiated liposarcoma (Chua, Lee, and Dominguez 2017). CK2β transcript 
expression is also down regulated in Barrett’s esophagus, esophageal adenocarcinoma, 
and follicular lymphoma (Chua, Lee, and Dominguez 2017). There are also conflicting 




CK2β transcripts for a given type of cancer while other studies claim  the contrary, such 
as in CLL (Chua, Lee, and Dominguez 2017). Because the CK2β subunit of the CK2 
protein is a regulatory subunit, understanding other mitigating factors around the aberrant 
expression of CK2 in various cancer types, as well as how this variation in transcript 
expression may create downstream changes in protein expression and protein function, 
may be critical to develop therapeutics targeting CK2.  
Table 3. Cancer Dependent Changes in CK2β Transcript Expression 




Astrocytoma 1.518 3.12x10-4 Shai Brain 




1.761 4.56x10-7 D’Errico Gastric 
Floor of Mouth 
Carcinoma 
1.923 1.44x10-4 Pyeon Multi-
Cancer 
Clear Cell Renal Cell 
Carcinoma 
1.506 4.79x10-8 Jones Renal 
Seminoma (not 
otherwise specified) 
-2.180 2.11x10-6 Korkola 
Seminoma 
Testicular Teratoma -2.471 0.009 Skotheim Testis 
Teratoma (not otherwise 
specified) 




-1.815 0.007 Detwiller 
Sarcoma 






-2.042 4.9x10-9 Kim Esophagus 
Follicular Lymphoma -1.493 4.37x10-8 Compagno 
Lymphoma 
 (Table adapted from Chua, Lee and Dominguez, 2017)  
Use of CK2 Protein Levels and Transcript Expression as a Prognostic Indicator 
CK2 protein levels and transcript expression have both also demonstrated  
potential to be used as diagnostic or prognostic indicators (Chua, Lee, and Dominguez 
2017). In previous meta-data research using Kaplan-Meier analysis, it has been shown 
that the CK2 transcript, CK2αP, has prognostic value in cervical cancer (Chua, Lee, and 
Dominguez 2017). In cervical cancer, higher expression of CK2αP transcripts levels 
correlates directly with lower survival levels, determined via Kaplan-Meier analysis, 
pointing to prognostic value for CK2αP in cervical cancer (Chua, Lee, and Dominguez 
2017).  Further, CK2α and CK2β transcripts levels and protein levels have previously 
been reported as potential prognostic markers in gastric carcinoma based on a similar 
Kaplan-Meier plot analysis (Chua, Lee, and Dominguez 2017). Interestingly, in head and 
neck squamous cell carcinoma (HNSCC), both CK2 protein activity and transcript levels 
can be used as prognostic markers based on meta-database analysis done by Chua et al,  
performing statistical analysis of data curated using oncomine and USCXena databases 
(Chua, Lee, and Dominguez 2017).  Kaplan-Meier analysis of this data showed that 
higher expression of the CK2α’ and CK2β trannscripts directly correlate with lower 




CK2 protein activity, both nuclear and cytosolic, and this positively correlates with 
disease status and also correlates with decreased patient survival (Gapany et al. 1995). In 
renal cell carcinoma, Kaplan-Meier analysis has shown that higher transcript expression 
of CK2αP correlates with higher survival, giving it prognostic value in this cancer type 
(Chua, Lee, and Dominguez 2017). Hepatocellular carcinoma is another cancer in which 
CK2 transcripts can be prognostic indicators, with higher CK2α’ transcript expression 
being directly correlated with lower survival (Chua, Lee, and Dominguez 2017).  
Development of Therapeutics in CK2 inhibition in Cancer  
Previous experiments have shown that therapeutic interventions targeting CK2 to 
be efficacious in causing cancer cell death and this has been shown using several 
approaches (Gray et al. 2014; Wang et al. 2001). The approaches in targeting CK2 have 
been very diverse in strategy and modality including use of selective pharmacological 
inhibitors, molecular inhibitors, as well as mRNA-level inhibition. Various CK2 selective 
inhibitors have also been used to directly inhibit CK2, thereby decreasing CK2 activity 
and inducing cell apoptosis (Di Maira et al. 2005; Gray et al. 2014). The CK2 inhibitor 
CX-4945 has been shown to downregulate NF-κB, PI3K/Akt and JAK/STAT3 signaling 
in glioma, while also increasing survival time in a glioma intracranial murine model 
(Gray et al. 2014). The use of an antisense CK2α oligonucleotide (ODN), as well as an 
antisense CK2β ODN to treat cancer cells resulted in apoptosis in these cells (Huamin 
Wang et al. 2001). More recently, combinations of both CK2 ASOs and selective 




potential to be used in combination with traditional, well-known chemotherapeutic agents 
to provide sustained efficacy and overcome. For example, sensitization of NSCLC cells 
(H157 and A549 cells lines) to cisplatin via inhibition of CK2 has been displayed through 
use of siRNA designed to target CK2α, and treatment of NSCLC cells with CK2α siRNA 
and cisplatin-enhanced apoptosis induced by cisplatin when compared to treatment of 
cells with cisplatin alone (Yang et al. 2017). In addition, apoptosis induced by cisplatin 
was to a far greater extent when used in combination with CK2α siRNA than cisplatin 
alone (Yang et al. 2017). Discoveries such as this have prompted the use of many known 
CK2 inhibitors in combination with cisplatin to treat NSCLC cells to determine the 















1. Characterize the development of individual CK2 inhibitors and their use in 
various cell models, xenograft models, as well as clinical trials. 
2. Detail current research into the use of CK2 inhibitors in combination with 
traditional chemotherapeutics.  
3. Discuss development and structural design of new small molecule CK2 inhibitors 
and efficacy shown in cell models.  
4. Discuss future directions for CK2 inhibitor development and likely avenues to 



















Specific Inhibitors of CK2 
 CK2 inhibition has long been studied and there are a handful of potent CK2 
inhibitors that have been shown to have targeted effects and inhibit CK2 at IC50 values 
that are deemed within the acceptable range. These inhibitors include CX-4945 
(silmitasertib), CIGB-300, TBB, IQA (chemical name [5-oxo-5,6-dihydroindolo-(1,2-
a)quinazolin-7-yl]acetic acid ), DMAT (chemical name 2-dimethylamino-4,5,6,7-
tetrabromobenzimidazole), Apigenin, Emodin, among others.  
 
CK2 Inhibition in Cells.  The vast majority of studies on CK2 inhibitors have occurred in 
cell models, due to the relative novelty of various CK2 inhibitors and their mechanisms 
of action. CX-4945 inhibits CK2 by acting on the ATP-binding pocket of CK2, 
preventing the kinase from binding ATP, which is crucial to the function of CK2 (Perea 
et al. 2004). In glioblastoma (GBM), CX-4945 outperformed the current standard of care, 
TMZ, in GL261 cells. CX-4945 had a far lower EC50 than TMZ, with TMZ (10,000 uM) 
decreasing cell viability by 60% and concentration of CX-4945 (500 uM) decreasing cell 
viability by 80% (Ferrer-Font et al. 2017). Treatment of GBM cells with CX-4945 also 
causes senescence after 72 hours of treatment and alters cell cycle distribution causing 
more cells to stay in the G2/M phase, and reducing cell proliferation and inducing 
apoptosis (Zheng et al. 2013). Further, treatment of GBM cells with CX-4945 showed 




constitutive AKT activation, reduced JAK/STAT activation, as well as suppression of 
NF-κB p65 activation (Ferrer-Font et al. 2017; Zheng et al. 2013). CX-4945 treatment of 
GBM cells (U251-MG, X1016, and U87-MG cell lines) has also shown reduced cell 
adhesion as well as decreased migration of cells  (Zheng et al. 2013).  In addition, 
treatment of ficoll purified leukemia cells (CLL, AML, B-ALL, T-ALL, lymphomas, 
CML, CMML) harvested from patients treated with CX-4945 in concentrations ranging 
from 10 nM to 10uM showed a median IC50 of all samples to be 6.7 uM, with CX-4945 
being most active in lymphoid samples (Prins et al. 2013). Similarly CX-4945 has also 
been used to treat T-ALL cells, where NOTCH1 has become a target of interest due to 
proto-oncogene MYC being a transcriptional target of  NOTCH1, and the success seen in 
suppressing NOTCH1 signaling using gamma secretase inhibitors (Lian et al. 2017). 
Treatment of T-ALL cell lines JURKAT and ALL-SIL with CX-4945 induced apoptosis 
and decreased survival in both cell lines tested as well as a destabilization of NOTCH1, 
and reduction of MYC transcripts within 8 hours of treatment (Lian et al. 2017). Pre-
treatment of Jurkat cells with CX-4945 (10 uM) for two hours with subsequent 
PMA/PHA activation (classical method to stimulate IL-2 production) has shown 
decreased mRNA expression and production of IL-2 when compared to control (J.-I. Jung 
et al. 2018). A separate B-cell acute lymphoblastic leukemia (B-ALL) model using SEM 
and RS4;11 cells showed that PTEN, AKT, and 4EBP1 (downstream signaling protein) 
decreased phosphorylation compared to controls. Further, the B-ALL model also found 
significantly decreased metabolic activity and cell proliferation in comparison to controls 




and REH cells) (Richter et al. 2019). Separately, treatment of acute myeloid leukemia 
(AML) cells (MOLM-13 and HL60 cell lines) with CX-4945 restored levels of protein 
phosphatase 2A (known tumor suppressor) in which p38β was overexpressed (p38β 
reduces PP2A activity) (Arriazu et al. 2020). In AML cells treated with CX-4945 also 
caused cytosolic depletion of oncoprotein SET (oncoprotein phosphorylated by CK2 and 
shown to inhibit PP2A activity) and accumulation of SET in the nucleus which also led to 
increased PP2A activity (Arriazu et al. 2020). In gastrointestinal stromal tumors (GIST), 
CK2 overexpression has been demonstrated in patient derived GIST cell lines (GIST882, 
GIST4300/654, GIST-T1), and treatment of GIST cell lines for 6 hours with CX4945 led 
to decrease in phosphorylated CDC37 (p-CDC37), KIT (p-KIT), AKT (p-AKT), S6 (p-
S6) (Huang et al. 2020). This was determined to be indicative of KIT/PI3K/AKT/mTOR 
signaling inactivation due to dephosphorylation of CDC37, leading to inactivation of 
downstream signaling through AKT and S6 (Huang et al. 2020). A cell model for prostate 
cancer has also been developed (PC3 cell line) in which CX-4945 treatment of cells 
markedly reduced PI3K/Akt signaling (shown by dephosphorylation of Akt at multiple 
sites and reduced phosphorylation of downstream AKT targets) (Pierre et al. 2011). In 
addition, treatment of these prostate cancer cells with CX-4945 also induced apoptosis as 
well as caused cell cycle arrest (Pierre et al. 2011). CX-4945 has also shown promise in 
cholangiocarcinoma cell models, with treatment of cells with CX-4945 showing 
significant reduction in cell viability in a manner that was dose-dependent (in HuCCT1, 
EGI-1, Liv27 cells) and time-dependent (shown in HuCCT cells) (Zakharia et al. 2019). 




significant apoptosis seen at 48 hours with higher CX-4945 doses (7.5-10uM) and lower 
doses (2.5 uM-5uM) showing significant induction of apoptosis at 72 hours of treatment 
(Zakharia et al. 2019). Treatment of cholangiocarcinoma cells with CX-4945 also showed 
inhibition of colony formation, and decreased PI3K/AKT signaling (Zakharia et al. 
2019). In osteosarcoma cell models, treatment with CX-4945 of Saos-2, NY, U2OS, and 
143B cell lines has shown a significant decrease in cell proliferation and an increase in 
apoptosis in SaOS-2 and 143B cell lines (confirmed at 48 and 72 hours by increased 
cleaved PARP, increased cleaved caspase-3, decreased Bcl-2 and Bcl-xL expression, all 
markers of apoptosis) (Takahashi et al. 2017)  
CIGB-300 is a novel peptide generated and developed by Perea in 2004. Its 
mechanism of action is to bind the phosphoacceptor site on CK2 substrates and thereby 
interfere with the function of the phosphoacceptor site (Perea et al. 2008). CIGB-300 has 
also been used in several cancer cell models. In several lung cancer cell models, 
(including H125, NCI-H125, A-549 cell lines) treatment with CIGB-300 has been shown 
to both inhibit cell proliferation and decrease cell viability (Cirigliano et al. 2017; Perera 
et al. 2014). Furthermore, in lung cancer cell lines H125 and 3LL, cell adhesion was 
reduced by up to approximately 60% by treatment with CIGB-300 (at concentrations 
ranging from 10uM-50uM), and incubation of H125 cells with sub-IC50 concentrations of 
CIGB-300 for 2-3 hours inhibiting cell spreading by approximately 40% (Benavent 
Acero et al. 2017). Previous markers associated with tumor invasion and metastatic 
spread, uPA and MMP2, were found to also be modulated by cell treatment with CIGB-




cell lines with CIGB-300 at low lethal dose also showed reduced nuclear levels of 
p65/relA (NF-κB complex subunit), however in the cytoplasm an accumulation of p65 
was seen, indicative of inhibition of the activating phosphorylation of CK2 that is 
required to allow for translocation of the NF-κB complex to the nucleus. This inhibitory 
effect was still seen even after addition of PMA (known activator of NF-κB) (Cirigliano 
et al. 2017). Treatment of lung cancer cells (NCI-H125 cell line) with CIGB-300 has also 
shown inhibition of CK2 phosphorylation of B23/NPM (nucleolar protein that is 
commonly aberrantly expressed in neoplastic tissue) (Perera et al. 2015). More recently, 
CIGB-300 was used in breast cancer cell lines with well documented capability for 
metastatic colonization (Gottardo et al. 2020). CIGB-300 decreases breast cancer cell 
growth in a dose dependent manner, causes a sub-G0  cell cycle arrest in all breast cancer 
cell lines examined (significant arrest occurs in S phase in MCF-7 and F3II cell lines and 
G0/G1 transition in MDA-MB-231 cells), and also increases apoptosis of breast cancer 
cells (Gottardo et al. 2020). In more invasive, aggressive and migratory breast cancer cell 
lines MDA-MB-231 and F3II, treatment with CIGB-300 at an established IC50 
concentration reduced migration by 50% in MDA-MB-231 and 90% in F3II (Gottardo et 
al. 2020). CIGB-300 was also used to treat CLL cells (MEC1, WaC2CD5, JVM3, 
MO1043 cells) all showed decreased viability in dose-dependent and time-dependent 
fashion with IC50 of CIGB-300 for all the cell lines being between 27 and 38 uM (Martins 
et al. 2014). Because previous data on CLL has shown that PI3K-mediated signals are 
required for cell survival in vitro, it is notable that inhibition of CK2 via treatment with 




phospho-S380), as well as decreased phosphorylation of PI3K downstream targets 
(AKT/PKB and GSK-3β) showing overall decrease in activation of PI3K signaling 
pathway (Martins et al. 2014). CLL Primary CLL samples obtained from patients showed 
a similar trend when treated with CIGB-300 as the aforementioned cell lines; however 
12.5 uM of CIGB-300 was able to decrease the viability in patient CLL samples 
significantly (Martins et al. 2014). CIGB-300 has also been used to treat T-ALL cells 
(MOLT4 and HPB-ALL cell lines) in a model that found CIGB-300 decreases viability 
and proliferation in a dose-dependent manner, and was also found to promote apoptosis 
in HPB-ALL cells. These effects were not found to be blocked by addition of IL-7 to cell 
culture conditions (IL-7 signaling previously shown to inhibit apoptosis and increase 
proliferation of T-ALL cells) (Perera et al. 2020). Addition of IL-7 to cell cultures 
activates the JAK/STAT pathway. Pretreatment of cells with CIGB-300 blocked the 
activation of the JAK/STAT pathway (Perera et al. 2020). In this model it was also 
discerned that in HPB-ALL cells, CIGB-300 treatment inhibits CK2 phosphorylation of 
B23/NMPI at the serine 125 residue, as well as inhibits CK2 phosphorylation of PTEN 
(at Serine380) and Akt (at Serine 129); these effects were confirmed by observation of 
decreased phosphorylation of downstream PI3K/AKT targets (Perera et al. 2020). 
CK2 inhibitor TBB has been used in cell models and found to generate responses 
in several cell lines that include different cancer types. In glioma cell lines U87MG and 
T98G, treatment with TBB for 24 hours reduced ATP production and glucose uptake  
(Dixit et al. 2016). The treatment of these glioma cell lines with TBB also exhibited an 




AMPK inhibitor which indicates that CK2 inhibition in glioma cells affects cell viability 
and metabolism in a way that is dependent on PDK4-AMPK (Dixit et al. 2016). 
Neuroblastoma cells treated 50 uM TBB for 1 hour led to Ikaros expression increase, 
which is significant because Ikaros is a transcriptional factor phosphorylated by CK2, 
which has impacts on Ikaros cell cycle regulating effects (Arco, Maki, and Georgopoulos 
2004; Lee et al. 2010; Cho et al. 2008). This effect of TBB on Ikaros expression was 
further confirmed by treatment of neuroblastoma cells with acrylamide (found to reduce 
Ikaros expression) with or without TBB, with presence of TBB preventing acrylamide 
from reducing Ikaros expression (Lee et al. 2010). In a prostate cancer cell model (PC3-
LN4 cells) it was shown that treatment with 80 uM TBB causes a change in cell viability 
within 2 hours, with cell viability being 40% at 24 hours and 22% at 48 hours (Qaiser et 
al. 2014). TBB treatment of PC3-LN4 and LNCaP cancer cells also led to loss of 
mitochondrial membrane potential (indicator of apoptosis) in a concentration-dependent 
manner within 2 hours , with the effect persisting for 24 hours; a lesser response was seen 
however in benign prostate cells (BPH-1) (Qaiser et al. 2014). Reduction of cell viability 
and induction of apoptosis have also been shown in prostate cancer cell line 22Rv1 
(Schneider et al. 2010). Furthermore in both androgen-sensitive prostate cancer cell lines, 
LNCaP and 22Rv1, treatment of cells with TBB increased p53 expression. However it 
was determined that cleavage of PARP (marker for apoptosis) was not dependent on p53 
expression as was unchanged with siRNA p53 downregulation (Schneider et al. 2010). 
TBB has also been used in breast cancer cells (MDA-MB-231), with TBB pre-treatment 




decreasing overall cell viability (Gray et al. 2014; Fritz, Issinger, and Olsen 2009). 
Treatment of breast cancer cells (MCF-7 cells) with TBB also has been shown to alter 
microRNAs in a manner that is associated with decreased proliferation and increased 
apoptosis (D. Li et al. 2014). TBB treatment also led to cell cycle arrest in G0/G1 phase, 
shortening of S phase in a dose-dependent manner, as well as an increase in apoptotic 
cells with increasing TBB concentrations after 24 hours in comparison to controls (D. Li 
et al. 2014). In a GBM model (T98G cell line), TBB treatment showed significant cell 
growth inhibition after 24 hours and decrease in cell viability after 48 hours. There was a 
dose-dependent decrease in number of neoplastic cells after 48 hours when compared to 
controls (Pucko, Ostrowski, and Matyja 2019).  
IQA shows tremendous selectivity for CK2. When tested against a panel of 
kinases, in the presence of ATP and IQA, the only kinase with greater than 90% 
inhibition was CK2 and all other kinases in the panel had less than 50% inhibition (Sarno 
et al. 2003). Treatment of Jurkat cells with IQA drastically inhibits CK2 when compared 
with control cells (Sarno et al. 2003). Jurkat cells treated with concentrations of the 
“open” form of IQA (less effective inhibitor of CK2 than standard IQA) and standard 
IQA up to 160 uM for 24 hours have shown decreased cell viability relative to the control 
(Sarno et al. 2005). The pro-apoptotic effect is more effective in the “open” form of IQA, 
showing greater reduction of cell viability at maximum concentration (90% reduction in 
cell viability) than the standard form of IQA (~30% reduction in cell viability). This 
could be due to the increased permeability of the “open” form of IQA, or that it induces 




DMAT (2-dimethylamino-4,5,6,7-tetrabromobenzimidazole) has been used in a 
wide range of cancer cell models, showing efficacy in inhibiting CK2 (IC50 value of 0.15 
uM for DMAT inhibition of CK2) and greatly decreasing the ability of cancer cells to 
proliferate and retain viability (Pagano et al. 2004). DMAT (25 uM) effectively induces 
apoptosis in HeLa cells 12 hours after treatment, in a fashion not solely dependent on 
CK2 activity, as induction of apoptosis was still observed in HeLa cells expressing 
inhibitor resistant forms of CK2α and CK2α’ (Duncan et al. 2008). DMAT has also been 
used in glioma cell lines, such as C6 glioma cells, and shown reduced cell proliferation, 
G1 growth arrest in cell cycle (indicated by decrease of phosphorylated retinoblastoma 
protein), as well as induction of apoptosis indicated by morphological changes in cells 
typical of apoptosis (retreating of cell extensions, cell shrinkage membrane blebbing) 
(Kaminska et al. 2009). Colon cancer cell models treated with DMAT decreased cell 
proliferation as well as increased levels of apoptosis in all cell lines tested (Yefi et al. 
2011). CK2 inhibition with DMAT was also found to reduce cyclooxygenase-2 mRNA 
and protein levels in several types of colon cancer cell lines as well as breast cancer cells 
in a dose-dependent manner. (Yefi et al. 2011) DMAT has also been used for treatment 
of cells in an intriguing breast cancer cell model, in which anti-estrogen resistant cells 
MCF-7 were investigated for their sensitivity to DMAT (Christina Westmose Yde et al. 
2007). Interestingly, DMAT was more effective in treating anti-estrogen resistant MCF-7 
cells (resistance developed via treatment with anti-estrogen agent Tamoxifen) than 
parental MCF-7 cells, although all MCF-7 lines investigated had inhibited growth, and 




2007). When analyzed for morphological changes that are typically seen in cell death, 
evidence was only seen in MCF-7 anti-estrogen resistant cells (~40% cell death) but not 
in parental MCF-7 cells (Christina Westmose Yde et al. 2007). H295R adrenocortical 
carcinoma cells were treated with DMAT and led to significant reduction of cell viability 
72 hours post-treatment at concentrations 100 nM to 100 uM, and significant inhibition of 
cell proliferation occurred after 72 hours post-treatment at the same concentrations 
(Lawnicka et al. 2010). Treatment of these cells with DMAT also significantly decreased 
cortisol, aldosterone, dehydroepiandrosterone sulfate, and androstenedione secreted by 
H295R cells 72 hours post-DMAT treatment, but caused an accumulation of 17-OH-
progesterone in culture medium; this is significant because ACC patient mortality is 
affected by hormonal activity (Kirschner 2006; Lawnicka et al. 2010). DMAT has also 
been used in a hepatocellular carcinoma (HCC) cell line model, using HepG2 cells as 
well as Huh-7 cells (Sass et al. 2011). 72 hour treatment of these HCC lines with DMAT 
(1uM used in HepG2 cell line and 10 uM in Huh-cells) significantly reduced cell 
proliferation (Sass et al. 2011). At a higher DMAT treatment concentration (<30 uM in 
HepG2 cells and 40 uM in Huh-7 cells), apoptosis was induced after 24 hours of 
treatment which shows that DMAT mostly interferes with proliferation but at higher 
concentrations is capable of inducing apoptosis (Sass et al. 2011). Significantly, it was 
also found that DMAT treatment of the aforementioned HCC cell lines interfered with 
NF-κB activity and Β catenin regulated transcription (Sass et al. 2011). DMAT has also 
been nano encapsulated in tenfibrigen and delivered to prostate cancer cells (PC3-LN3 




cancer cells and not benign cells (Trembley et al. 2012). Viability of benign cells was 
unchanged by concentrations of TBG-DMAT that caused 90% inhibition of proliferation 
in prostate cancer cells, with loss of CK2 activity seen in TBG-DMAT treated PC3-LN4 
cells  (Trembley et al. 2012). 
Apigenin has been found to inhibit CK2 as well, and shown success in treating 
multiple types of cancers in cell models. Renal cell carcinoma cell lines ACHN, 786-0, 
and Caki-1 cells were treated with Apigenin at concentrations from 5-80 uM in a dose-
dependent and time-dependent fashion (Meng et al. 2017). Importantly, the IC50 of 
Apigenin in the cancer cell lines examined was no higher than 51 uM in 24 hour 
treatment and no higher than 21.4 uM in 48 hour treatment, with HK-2 cells (normal 
epithelial cells of the renal proximal tubule), being far less susceptible with an IC50 of 
122.1 uM in 24 hour treatment and 70.2 uM in 48 hour treatment (Meng et al. 2017).  
Emodin has also shown the ability to inhibit CK2. It has been determined in HCC 
cell model (HepG2 and Hep3B cell lines) that treatment with emodin-enhanced rTRAIL-
induced apoptosis as well as increased FasL-induced apoptosis, and in the absence of 
rTrail or FasL emodin also induced a dose-dependent apoptosis/cell death of HepG2 cells 
(H.-R. Kim et al. 2008). In these HCC lines, co-incubation of HCC cells with NK cells 
led to significantly more NK-mediated apoptosis in the presence of emodin when 
compared to co-incubation without emodin (H.-R. Kim et al. 2008). Emodin treatment of 
cervical cancer cells (HeLa cells) in the presence of either FasL or rTrail, augmented both 
apoptosis responses and treatment with emodin alone induced apoptosis to a greater 




cells, emodin treatment was also found to augment NK-mediated apoptosis (H.-R. Kim et 
al. 2008). HeLa cells also were found to have downregulated AKT kinase, mTOR kinase 
inhibition, as well as modulated MAP kinase signaling pathways in response to emodin 
treatment (Olsen, Bjørling-Poulsen, and Guerra 2007). In a prostate model using LNCaP 
cells and PC3-AR (both androgen sensitive lines), and PC3 and DU-145(both far less 
androgen sensitive), treatment with emodin decreased the cell proliferation to a far 
greater degree in the androgen sensitive lines (Cha et al. 2005). It was also observed in 
LNCaP and PC3-AR cells, that emodin treatment prevented nuclear translocation of the 
androgen receptor, inhibited transcriptional activity of the androgen receptor, and induced 
androgen receptor degradation via a proteasome mediated pathway (Cha et al. 2005). In a 
breast cancer cell model (MCF-7 cells) that has invasive capability, treatment with 
emodin greatly reduced PKC-induced invasion by decreasing MMP-9 expression in cells 
(cell invasion induced through use of TPA) (J.-M. Kim et al. 2018, 218).  
Quinalizarin, a specific CK2 inhibitor, has been used in multiple cell models 
showing efficacy in providing anticancer effects. Quinalizarin has been found to reduce 
CK2 activity in lung cancer cells (K. Li et al. 2019; Q. Li et al. 2017). In both wild-type 
and EGFR-resistant human adenocarcinoma lung cancer/NSCLC cell lines treatment with 
quinalizarin induced apoptosis, suppressed cell growth, and decreased cell viability 
(H1650, H1975, PC9 and A549 cell lines showed increased apoptosis rate; H1650, 
H1975, H460, A549, PC9 and HCC827 cell lines showed decreased cell viability) (K. Li 
et al. 2019; Q. Li et al. 2017; Zhou et al. 2015). Further, treatment of H460 and A549 cell 




comparison to DMSO control, altering cell cycle distribution (Q. Li et al. 2017). 
Quinalarizin treatment of several lung cancer cell lines (A549, H446, H460) has also 
been shown to inhibit cell migration (Zhou et al. 2015).  
 
CK2 Inhibition in Xenograft Models 
 Much of the important and useful information on CK2 inhibition and its efficacy 
has come from xenograft animal models, as this has provided a method to study immune 
modulation as well as advanced stage cancer types that are difficult to study in patients.  
In mice inoculated with GBM intracranially (GL261 cells), administration of CX-
4945 daily for 25 days reduced CK2 activity by 17 fold (Ferrer-Font et al. 2017). In 
another GBM model (mice inoculated with X1046 cells), CX-4945-treated mice 
exhibited 76.4% tumor growth inhibition, with these mice showing significantly less 
AKT, STAT-3, and NF-κB levels compared to control mice (Zheng et al. 2013). 
However, the effect of CX-4945 treatment on survival in GBM xenograft models appears 
to vary with the model, as a GL-261 model reported no significant improvement in 
survival of treated mice in comparison to control group, whereas in a X1046 GBM 
xenograft model mice treated with CX-4945 having a significantly improved median 
survival time in comparison to vehicle-treated control group (Ferrer-Font et al. 2017; 
Zheng et al. 2013). In an acute B-lymphoblastic leukemia (B-ALL) xenograft model 
(SEM-GFP-luciferase cells used to generate tumors), mice treated with CX-4945 showed 
delayed B-ALL cell proliferation until day 24 in comparison to controls (Richter et al. 




been established to test CX-4945 efficacy, and it was determined that CX-4945 showed 
anti-tumor effects in a dose dependent fashion, and at the highest dose (75 mg/kg) tumor 
growth inhibition was 86% (Pierre et al. 2011). In this prostate cancer xenograft model 
there was also a significant reduction in micro vessel density in CX-4945-treated mice, 
indicating that part of the efficacy of CX-4945 comes from inhibition of angiogenesis 
(Pierre et al. 2011). In a cholangiocarcinoma xenograft model (HuCC1 cells), mice 
treated with CX-4945 showed further decreased cell proliferation (Ki67 staining) and 
increased apoptosis (TUNEL staining) when compared to both control mice as well as 
mice treated with standard of care regimen (cisplatin and gemcitabine) (Zakharia et al. 
2019). Mice in this cholangiocarcinoma xenograft model treated with CX-4945 also 
showed significantly less tumor volume than control mice; however, tumor volume from 
the CX-4945 was significantly higher than the group treated with cisplatin and 
gemcitabine (Zakharia et al. 2019). An osteosarcoma xenograft model has also been 
established in nude mice, inoculated with 143B cells (osteosarcoma cell line) and CX-
4945-treated mice showed significant inhibition of tumor growth and increase in survival 
in comparison to control mice (Takahashi et al. 2017) 
CIGB-300 has also been used in several xenograft experiments, showing promise 
in inhibiting cancer development, particularly showing efficacy in preventing metastasis 
and invasion. This was shown in a lung cancer model with mice inoculated with 3LL 
cells to establish nodules in the lung, and subsequently treated with 10 mg/kg dose for 
five consecutive days. Reduced metastasis and lung colonization were observed 




10 mg/kg CIGB-300 via intravenous injection for 5 consecutive days and sacrificed 21 
days after cancer inoculation, pulmonary nodules were significantly decreased in the 
group treated with CIGB-300 in comparison with the control group, also showing an 
approximately 45% decrease in number of metastatic lesions (Gottardo et al. 2020). 
Further, using this xenograft model, it was discovered that postoperative administration 
of  CIGB-300 after incomplete removal of F3II mammary tumors led to an approximately 
60% reduction in total number of lung nodules and inhibition of secondary F3II lung 
lesions by 83% when compared to vehicle-only animals, as well as significant reduction 
in macro metastatic disease in the treated group versus the control (85.7% in control 
group versus 42.8% in the CIGB-300 treated group) as well as significant reduction in 
mice with heavily colonized lungs (71.4% in control group vs 0% in the CIGB-300 
treated group) (Gottardo et al. 2020). CIGB-300 has also been used to treat mice (20 mg/ 
kg) xenografted with CLL cells (M01043) subcutaneously, and results have shown that 
mice treated with CIGB-300 displayed a significant delay in tumor growth, with 
differences between CIGB-300-treated group and vehicle-treated group emerging after 1 
week of treatment and becoming more pronounced with time (Martins et al. 2014). 
TBB has also been used in xenograft models to attempt to translate successful 
CK2 inhibition in cell models. One such model is a nude mice xenograft using U87 
glioma cell line injected subcutaneously in the flank of anesthetized nude mice, and 
subsequently treated with either vehicle or 10mg/kg of TBB for 25 days (Dixit et al. 
2016). Treatment with TBB in this model was found to lead to a significant decrease in 




body weight during the course of treatment (Dixit et al. 2016).  Further, the TBB-treated 
group also displayed inhibition of glioma cell proliferation, an increase of p53 levels, in 
addition to an increase in cell-cycle regulator p21 and corresponding decrease in cell-
cycle regulator cyclin D1 (Dixit et al. 2016). TBB has also been used as a single therapy 
in WiDr cell (human colorectal carcinoma cells) xenograft mice, and TBB-treated WiDr 
mice showed reduced tumor growth as well as tumor growth delay (Zwicker et al. 2021). 
There was also an increase in rate of apoptosis when compared to untreated control mice 
(Zwicker et al. 2021).  
DMAT has been used in xenograft models due to its efficacy in decreasing cell 
viability in several cell models, including some cell lines resistant to first-line therapeutic 
options for various cancers. In an HCC xenograft model, HepG2 cells were 
subcutaneously injected in the flank of male mice, and after tumors reached sufficient 
size, mice were treated with 500 ug/kg of DMAT or vehicle for 10 days (intraperitoneal 
[I.P.] route of administration) (Sass et al. 2011). Mice treated with DMAT had 
significantly slower tumor growth in comparison to control mice, as well as significantly 
decreased proliferation in tumor tissue of mice treated with DMAT (shown by 
immunohistochemical staining with proliferation marker Ki67 (Sass et al. 2011). DMAT 
has also been delivered in a tenfibgen (TBG) nano capsule via intravenous (IV) and I.P. 
administration routes in treatment of prostate cancer xenograft mice inoculated with PC3-
LN4 tumors via subcutaneous injection in the flank at approximately 8 weeks of age 
(Trembley et al. 2014). TBG-DMAT was more available to tumor cells in comparison to 




100 ug/kg led to a similar reduction in Ki-67 signal that was observed with unformulated 
DMAT treatment at 500 ug/kg; with tumors treated with 20 ug/kg TBG-DMAT showing 
a reduction in CK2α and CK2α’ signals as well as via immunoblot analysis (Trembley et 
al. 2014). There was also a significant reduction in the amount of overall immunoreactive 
NF-κB p65 protein, especially in the 20 ug/kg TBG-DMAT group (Trembley et al. 2014). 
Due to the success of emodin in several cell models, several research groups have 
also examined its efficacy in vivo. In one such prostate cancer xenograft model, mice 
were inoculated with PC3-AR tumors and treated with low dose (40mg/kg) emodin and 
showed a significant anti-tumor activity that was not seen in mice inoculated with PC3 
tumors (non-androgen sensitive) (Cha et al. 2005). Similar effects were observed in 
emodin-treated C3(1)/SV40 male transgenic mice (known to develop prostate cancer and 
eventually die), with these emodin-treated mice showing increased survival, increased 
weight gain and decreased AR expression in comparison to the control group (Cha et al. 
2005).  
Apigenin has been used in xenograft models as well, where nude mice were 
injected subcutaneously in the flank with ACHN cells, and Apigenin was administered 
via I.P. route every 3 days at 30mg/ kg (Meng et al. 2017). As a result of Apigenin 
treatment, tumor growth and volume were reduced, with Ki-67 index also determined to 
be lower, indicative of decreased cell growth (Meng et al. 2017).  
Quinalizarin has also been used in xenograft models due to the vast success it has 




were treated with quinalizarin ( mg/kg) and showed decreased Ki67 staining, as well as 
decreased tumor volume when compared to the control (Q. Li et al. 2017). 
 
CK2 Inhibitors in the Clinic 
 To date only CX-4945 and CIGB-300 have been tried in the clinic. There are 
several barriers for CK2 inhibitors to transition to the clinic, particularly selectivity of the 
CK2 inhibitor, as well as systemic toxicity and tolerability.  
 CIGB-300 has been administered in clinical trials for several cancer indications. 
Specifically, CIGB-300 was administered in a trial of women diagnosed with pre-
invasive cervical cancer, where subjects were given one out of four possible dose levels 
(14 mg, 70 mg, 245 mg, 490 mg) via intralesional injection for 5 consecutive days 
(Solares et al. 2009). Although no maximum tolerated dose or dose-limiting toxicity was 
achieved, it was determined that CIGB-300 was safe and tolerated well; however all 
patients experienced at least some local or systemic adverse events, with 82% being 
graded as mild, 17% moderate, and only 1 severe reaction. Most common adverse events 
included edema on injection site, erythema, necrosis, ulcer, lower abdominal pain, 
bleeding, and hematoma (Solares et al. 2009). The total lesion area decreased in all 
patients at 15 days post-CIGB-300 treatment, with response rates above 75% in all 
groups, with none of the patients showing lesion recurrence during the 12-month follow 
up and also showing no late adverse events (Solares et al. 2009). In culture of primary T-
ALL cells derived from pediatric patients at the time of diagnosis, treatment with CIGB-




2020). This is indicative of potential promise in use of CIGB-300 in vivo even where IL-7 
levels may be high (Perera et al. 2020).  
 
Combination of CK2 Inhibition with Other Therapeutics 
 CK2 inhibition has been shown to be efficacious in combination with traditional 
chemotherapeutics for which various cancers develop resistance mechanisms, such as 
lung, GI, prostate cancers, with CK2 seemingly having a sensitizing effect (Cirigliano et 
al. 2017; Jin, Song, and Pang 2019; Haiyun Wang et al. 2019).  
 
Combination Treatment in Cells 
CX-4945 has been used in combination with several well-known 
chemotherapeutics and similarly allowed for mitigation of cancer cell resistance 
mechanisms. For example in prostate cancer, androgen deprivation therapy (also referred 
to as anti-androgen therapy) is used in advanced-disease patients, but the disease 
progresses into a castration-resistant form (also referred to as castration resistant prostate 
cancer, CRPC) after an initial median response time of 18-20 months (Mostaghel, 
Montgomery, and Nelson 2009; Deng et al. 2017). Potential to mitigate this resistance 
has emerged through use of CX-4945, because in CRPC cell lines (22Rv1 and VCaP 
cells) use of CX-4945 downregulates AR-V7, an androgen receptor that plays a critical 
role in castration-resistant cancer cells at both a protein and transcriptional level (Deng et 
al. 2017). Subsequently, these cells are sensitized to anti-androgen therapy 




µMconcentrations of CX-4945 (Deng et al. 2017). In GBM, an increased efficacy has 
been documented when combining CX-4945 with TMZ, TMZ alone, or CX-4945 alone 
(Ferrer-Font et al. 2017). For example in GL261 cells, TMZ treatment alone at 1mM 
reduced cell viability to 82.8%+/-5.6%, CX-4945 treatment alone reduced cell viability to 
59.2%, and treatment of GL261 cells with 1mM TMZ and 30 uM CX-4945 reduced cell 
viability to 35.36% (Ferrer-Font et al. 2017). Similarly, a separate study was conducted in 
glioma cancer cell lines (SF767, U373, LN229) and also found that CX-4945 enhanced 
TMZ toxicity in glioma cells (Liu et al. 2019) . CX-4945 has also been shown to have a 
synergistic effect with diethylstilbestrol (DES), a synthetic form of estrogen, when used 
in Jurkat cells (T-ALL cell line), and increases inhibition of cell proliferation compared 
to either CX-4945 or DES treatment alone (J.-I. Jung et al. 2018). Pre-Treatment of 
Jurkat cells with a combination of CX-4945 (10 uM) and DES (3 uM) for two hours with 
subsequent treatment with PMA/PHA shows suppression of IL-2 mRNA expression and 
a decrease in overall IL-2 production to a greater degree than pre-treatment of cells with 
either CX-4945 or DES as single treatments (J.-I. Jung et al. 2018). Treatment of CLL 
cells harvested from patients and cultured in conditions that mimic CLL with 
combinations of CX-4945 and ibrutinib or CX-4945 and fludarabine has proven to be 
more efficacious in comparison to treatment of CLL cells with respective single 
treatments of ibrutinib or fludarabine, displaying a synergistic effect with either 
combination treatment (Prins et al. 2013). Similarly, CX-4945 also synergizes with BET 
bromodomain inhibitor JQ1 in T-ALL to induce apoptosis in T-ALL cells to greater 




being more sensitive to the combination of CX-4945 and JQ1 than either compound 
alone (Lian et al. 2017). PBMC cells were also found to be less sensitive to treatment 
with a combination of CX-4945 and JQ1 than T-ALL cells, indicating that there is 
promise in using this combination therapeutically with less risk of toxicity (Lian et al. 
2017). In AML models (HL60 and MOLM-13 cells) combined treatment with CX-4945 
and FTY720 (SET oncoprotein inhibitor) significantly decreased cell viability and 
increased apoptosis when compared to either treatment alone (Arriazu et al. 2020). These 
effects in AML cells also correlated with decreased cell migration and increased PP2A 
activity thus supporting the hypothesis that p38β contributes to reduction of PP2A 
activity, which also involves CK2 phosphorylation of the SET oncoprotein . CX-4945 has 
also been used in combination with cisplatin in treatment of NSCLC cells, specifically 
A549/DDP cisplatin-resistant cells (Jin, Song, and Pang 2019). This is of particular 
interest in non-small cell lung cancer (NSCLC) as care often involves use of cisplatin-
based chemotherapy, but resistance to cisplatin often develops and makes treatment of 
NLSC increasingly difficult (Spiro et al. 2004; Cirigliano et al. 2017). Treatment of 
A549/DDP cells with increasing concentrations of cisplatin (0, 1.25, 2.5, 5, 10, or 20 
ug/mL) in presence or absence of CX-4945 (15 uM) for 24 hours showed reduction of 
IC50 value for cisplatin in presence of CX-4945 indicating a sensitizing effect of CX-
4945 to cisplatin (Jin, Song, and Pang 2019). Treatment of A549/DDP cells  with both  
cisplatin and CX-4945 also significantly enhanced cisplatin-mediated apoptosis and 
increased apoptotic rate in comparison to cisplatin alone (Jin, Song, and Pang 2019). It 




Wnt/Β-catenin signaling, shown by significantly decreased protein and mRNA levels of 
p-DVL-2Ser143(significant protein associate with the Wnt/Β-catenin pathway), Β-catenin, 
C-Myc, and cyclin D1 in CX-4945 and Cisplatin combination treatment versus cisplatin 
treatment alone (Jin, Song, and Pang 2019). Targeting of CK2 and KIT has shown 
efficacy in treatment of gastrointestinal stromal cells as well tumor specimens (Huang et 
al. 2020). Use of CX-4945 in combination with KIT inhibitor imatinib in treating GIST 
cells lead to greater inactivation of the aforementioned KIT/PI3K/AKT/mTOR pathway 
than treatment with imatinib or CX4945 (Huang et al. 2020). Treatment of GIST cells 
with Imatinib and CX-4945 also led to greater decreases of cell viability than either 
treatment alone in all 4 GIST cell lines tested, including GIST882, GIST430/654, and 
GIST48 cells, all of which had minimal change in cell viability when treated with CX-
4945 alone at 2.5 uM or 5 uM (Huang et al. 2020). Dual targeting of KIT and CK2 
through use of imatinib and CX-4945 in combination also showed increased anti-invasive 
effects on GIST cells compared to either treatment alone, as determined by a wound-
closure assay (Huang et al. 2020). In a separate gastric cancer cell model using SNU-1 
cells, known to develop resistance to paclitaxel, combination treatment with both CX-
4945 and paclitaxel showed significant synergistic effects, specifically in inhibition of 
cell proliferation, increased proportion of cells in G2/M phase, as well as increased levels 
of apoptosis (M. Jung et al. 2019). SNU-1 cells treated with both CX-4945 and paclitaxel 
also displayed decreased phosphorylated levels of CK2, AKT, and 702S6K, indicative of 
overall decreased PI3K/AKT signalling (M. Jung et al. 2019). In a B-ALL cell model 




reduced metabolic activity to a greater extent than either therapy alone (Richter et al. 
2020). In cholangiocarcinoma the standard of care is treatment with gemcitabine and 
cisplatin which both act by inducing DNA damage, by increasing ratios of 
phosphorylated (activated form) DNA repair enzymes (XRCC1 and MDC1) (Zakharia et 
al. 2019). Treatment with both cisplatin/gemcitabine and CX-4945 significantly reduced 
ratios of phosphorylated DNA repair enzymes indicating that CX-4945 treatment 
abolished DNA repair pathway (Zakharia et al. 2019).  
CIGB-300 has also been shown to be efficacious in sensitizing chemotherapy-
resistant cancers. One such cancer that CIGB-300 has shown such effects is NSCLC, 
which is significant because of the aforementioned cisplatin-resistance that occurs in 
many patients. Cisplatin-resistance has long been thought to be due to NF-κB signaling, 
and this was confirmed in NSLC by treating H125 cells with cisplatin and seeing an 
increase in p65 levels in the nucleus, which were subsequently decreased by treatment 
with CIGB-300 (Cirigliano et al. 2017). In addition, in a cisplatin-resistant variant of the 
A549 cell line, combination treatment with cisplatin and CIGB-300 also showed a higher 
yet non-significant response than single treatments; however there was a significant 
reduction in IC50 of CIGB-300 when used in combination with cisplatin, displaying a 
sensitizing effect to CIGB-300 (Cirigliano et al. 2017). In another lung cancer cell line, 
treatment of NCI-H125 cell line with common chemotherapeutic paclitaxel and CIGB-
300 together produced a stronger cytotoxic effect than was seen in use of either 
compound as a lone treatment, confirming hypothesis of synergism between the two 




paclitaxel also caused cell cycle arrest at the S phase for 27% of cells and in the G2.M 
phases for 15% of cells (Perera et al. 2014).  
TBB has also been used in combination with common chemotherapeutics to treat 
various cancer cell models, to establish potential benefits in improving efficacy of current 
treatments. In uterine serous carcinoma for example, patients often develop resistance to 
platinum-based chemotherapy after surgical intervention, as well as high risk of 
recurrence in these patients (Zeng et al. 2019). Use of TBB (50 uM) to pretreat cells prior 
to treatment with cisplatin significantly reduced cell viability (Zeng et al. 2019). It is also 
of note that the aforementioned combination treatment with TBB and cisplatin also 
suppressed cisplatin-induced phosphorylation of Ser727 of STAT1 and decreased 
STAT1-related resistance to cisplatin, corroborating findings that phosphorylation of 
STAT1 serines increases cisplatin-resistance  (Zeng et al. 2019). TBB has also been used 
in combination with tumor irradiation in a WiDr cell xenograft model, in which mice 
were inoculated with WiDr cells in the right hind limb and mice were given TBB 150 
mg/kg twice daily for five consecutive days with or without radiation for five consecutive 
days (Zwicker et al. 2021). TBB-CK2 inhibition did not further increase tumor growth 
delay beyond radiation alone, however combination treatment of TBB and radiotherapy 
(Zwicker et al. 2021) . In addition, TBB treatment combined with radiotherapy 
significantly increased the rate of apoptosis in comparison to radiotherapy alone (Zwicker 
et al., 2021). TBB has also been used in combination with ZnSO4 to treat both prostate 
(P3 and DU145 cell lines) and breast cancer cells (MCF-7 and MDA-MB-231 cells); in 




greater reduction in cell viability than TBB or ZnSO4 treatment alone (Zaman et al. 
2019). Coupled with other experiments in these breast and prostate cancer models the 
conclusion can be drawn that CK2 is involved in zinc homeostasis in both breast and 
prostate cancer (Zaman et al. 2019). Because UV light has been found to upregulated 
CK2 activity, TBB has also been used in combination with UV light on lung cancer cells 
(A549 and H2030), and it was observed that combination treatment (TBB + UV light) 
induced greater apoptosis than UV alone (Kato et al. 2003; Zhao et al. 2013). Similarly, 
cell proliferation is also inhibited to a greater extent in TBB and UV combination 
treatment than UV treatment alone (Zhao et al. 2013). Because UV increases CK2 
activity and CK2 has been shown to degrade tumor suppressor PML, it is significant that 
TBB treatment of lung cancer cell lines A549 and H2030 recovers PML-decrease 
induced by UV treatment (Zhao et al. 2013).    
Quinalizarin has also been used to treat cells in combination with other anticancer 
compounds, especially those for which well-known cancer cell resistance mechanisms 
have developed. In human lung adenocarcinoma cell lines showing primary or secondary 
EGFR-TKI resistance (A549, H1650, H1975), treatment with quinalizarin and icotinib 
showed a far greater reduction of cell viability and a significant increase in apoptosis rate 
in comparison with icotinib or quinalizarin alone (K. Li et al. 2019). Interestingly, 
treatment with both quinalizarin and icotinib also reduced AKT and ERK protein 
expression in the aforementioned EGFR-resistant adenocarcinoma lung cell lines more 
than either icotinib or quinalizarin alone, which is indicative of a reduction in EGFR 




with mutated EGFR, use of EGFR-tyrosine kinase inhibitors provide improved median 
overall survival compared to traditional chemotherapeutics; however most NSCLC 
patients stop responding to tyrosine kinase inhibitors due to EGFR resistance (K. Li et al. 
2019; Ellis et al. 2015). In NSCLC models (A549 and H460 cells), quinalizarin has also 
been found to have a sensitizing effect on radiotherapy, as cells treated with increasing 
concentrations of quinalizarin and different doses of radiotherapy show decreased 
survival fractions with higher quinalizarin concentrations (Q. Li et al. 2017). 
Combination treatment of these NSCLC cells with quinalizarin and radiotherapy also led 
to enhanced suppression of cell proliferation in comparison to either treatment alone, as 
well as increased rates of apoptosis in comparison with radiotherapy alone; however the 
combination treatment did not show enhanced apoptosis rate when compared to 
quinalizarin treatment alone (Q. Li et al. 2017). Further, combination of quinalizarin and 
radiotherapy also increased the number of cells in the G2/M phase in comparison to 
either treatment alone (Q. Li et al. 2017). In a prostate cancer cell model using androgen 
sensitive LNCaP cells treatment with quinalizarin (50 uM) showed decreased expression 
of CK2, cdc25C (controls progression through G2-phase of cell cycle into mitosis), as 
well as CDK1 (target of cdc25C phosphatase which gets dephosphorylated leading to 
activation of cyclin B1/ cdk1 complex and entry into mitosis)  (Schneider et al. 2011; 
Karlsson-Rosenthal and Millar 2006).  
 




Several groups have deemed the success of combination treatments of CK2 
inhibitors with traditional chemotherapeutics in various cell models for aggressive 
growing cancers that stop responding to traditional chemotherapeutics intriguing enough 
to warrant testing if the sensitization and efficacy is also displayed in xenograft models. 
This also allows the opportunity to document tolerability in animal models, which allows 
for an estimation of tolerability in humans as for such a combination treatment. One such 
cancer type is glioblastoma, which has a well-documented poor median survival of 12-14 
months, with patients surviving two years after diagnosis at less than 10% (Gately et al. 
2017). With the most aggressive treatment with temozolomide (TMZ), median survival is 
still poor at 14.6 months (Stupp et al. 2005). To evaluate the potential of combination 
treatment with CX-4945 in mice, GBM tumor bearing mice (injected with GL261 cells 
intracranially) were treated with either three metronomic administrations (every 6 days) 
of TMZ or three metronomic administrations of CX-4945, or three metronomic 
administrations of both TMZ and CX-4945 (no treatment group was included as control), 
with combination treatment of both TMZ and CX-4945 outperforming TMZ alone in 
median survival (54.7 +/-11.9 days for TMZ +CX-4945  and 38.7 days +/- 2.7 days for 
TMZ alone) (Ferrer-Font et al. 2017). It is also worth noting that dosing regimen for the 
combination treatment of TMZ and CX-4945 had a significant effect, as administering 
three cycles of TMZ in combination with every day administration of CX-4945 produced 
significantly worse results than the aforementioned metronomic combination dosing 
schedule; with no differences found between the 3 cycle TMZ + everyday CX-4945 




et al. 2017). This has also been corroborated by a xenograft model in which mice were 
injected with SF767 cells in the brain, and treated with either TMZ alone, CX-4945 
alone, or with a combination treatment of both TMZ and CX-4945, with the combination 
treatment increasing survival and prolonged inhibition of tumor growth (Liu et al. 2019). 
In this glioma xenograft model, there was also an increase in apoptosis observed as well 
as a sizable decrease in tumor cell proliferation (Liu et al. 2019). Combined treatment of 
AML xenografted zebrafish embryos with FTY720 and CX-4945 showed decreased cell 
proliferation in significant fashion when compared to single agent treatments, as well as 
significantly decreased significantly reduced invasion of AML cells to the tail of the 
zebrafish (Arriazu et al. 2020). A B-cell acute lymphoblastic leukemia (B-ALL) model 
has been established in mice xenografts with SEM-GFP (luciferase tagged reporter line) 
and treated with both CX-4945 and decitabine (DEC) showed significantly reduced 
tumor cell proliferation when compared to DEC or CX-4945 alone (quantified by 
bioluminescent signal which is used as cell proliferation marker) (Richter et al. 2019). In 
a cholangiocarcinoma cell model using HuCCT1 xenografts, combination of CX-4945 
with standard cholangiocarcinoma therapeutics cisplatin and gemcitabine showed a more 
potent effect on reducing tumor growth, decreased cell proliferation (less Ki67 staining), 
increased apoptosis, as well as increased survival of mice in comparison to treatment with 
both gemcitabine and cisplatin without CX-4945 (Zakharia et al. 2019). However, there 
was no significant difference in cell viability between the group treated with CX-4945 
alone and the group treated with CX-4945, cisplatin, and gemcitabine (Zakharia et al. 




to compare the effects of combination treatment with paclitaxel and CX-4945 in 
overcoming paclitaxel resistance (M. Jung et al. 2019). In mice treated with both CX-
4945 and paclitaxel, there was significantly less tumor growth as well as significantly 
reduced levels of Ki-67 (proliferation marker), CK-2, and phosphorylated AKT when 
compared to mice treated with either monotherapy (M. Jung et al. 2019). 
Due to the success of CIGB-300 when used in combination with other 
chemotherapeutic agents, several preclinical models have been developed to examine if 
this success translates into in vivo animal models. One such model examined the use of 
CIGB-300 in combination with cisplatin in a cervical cancer model, inoculating nude 
mice with SiHa cancer cells and evaluating several dosing schemes, of either CIGB-300 
and cisplatin alone or in combination over the first 5 days of the experiment (Perera et al. 
2014). The lower dose combination scheme (CIGB-300 50 ug + cisplatin 1 mg/kg) 
resulted in more significant survival and tumor growth retardation than either 
monotherapy (77% growth inhibition in combination treatment, 50 ug CIGB-300 alone 
63% inhibition, 1mg/kg cisplatin alone 68% inhibition), but the higher dosing scheme in 
combination (CIGB-300 200 ug + 4mg/kg cisplatin) did not provide much benefit over 
using either monotherapy alone at a high dose (CIGB-300 200 ug alone or 4 mg/kg 
cisplatin alone) (Perera et al. 2014). 
 TBB has also been used in several xenograft models. In a uterine cancer xenograft 
model, mice were inoculated with Spac1L cells, the experimental group was pretreated 
with TBB from day 14 to day 21 following tumor inoculation and the (Zeng et al. 2019). 




group compared to DMSO pre-treated control group, and six-week survival rate in the 
TBB pre-treated group was 100% while the DMSO control group had a six-week survival 
rate of 67%. In ARK2 xenograft mice, TBB pretreatment with subsequent cisplatin 
treatment suppressed most tumor growth, while tumor growth suppression was not seen 
in the non-pretreated control, with other data from this study suggesting that a significant 
antitumor effect was conferred by inhibition of STAT1 Ser727 phosphorylation via pre-
treatment with TBB and subsequent cisplatin treatment (Zeng et al. 2019).  
 Quinalizarin has also been used in combination treatment of xenografts, with the 
reasoning being that its efficacy and selectivity for CK2 inhibition could sensitize various 
cancer cells to existing first-line therapeutics. One such model has been established in 
NSCLC, where mice bearing H460 tumors were treated with quinalizarin and 
radiotherapy either in combination or each treatment alone, with combination of 
quinalizarin and radiotherapy showed enhanced reduction of cell proliferation (Ki67 used 
as proliferation marker), and a more significant reduction in tumor growth when 










 CK2 has been found to be aberrantly expressed in many cancer types on DNA, 
RNA and protein levels, and inhibition through various modalities (antisense peptides, 
direct inhibitors, genetic knockout of CK2 genes, etc.) has shown promising anticancer 
effects. Inhibition of CK2 has been shown to be efficacious in the mitigation of pro-
cancer effects at the cell, xenograft, and clinical levels. Use of CK2 inhibitors in the 
treatment of cancer cells has shown particularly promising effects in decreasing cell 
proliferation, viability, and in certain cancers causing apoptosis and cell cycle arrest. 
Further, because several phosphorylation substrates of CK2 are in the JAK/STAT, 
PI3K/AKT, and NF-ΚB pathways, inhibition of CK2 through the aforementioned 
modalities has also displayed a significant decrease of signaling through these pathways, 
thus decreasing the cancerous effects of constitutive or abnormal signaling in these 
pathways. Many of these effects have been corroborated in vivo in xenograft experiments 
with mice treated with CK2 inhibitors showing enhanced survival, reduced tumor 
growth/volume, as well as increased presence of apoptotic markers and decreased 
proliferation in comparison to control mice. Further, tumor tissue obtained from several 
of these in vivo experiments has also shown decreased presence of phosphorylated CK2 
substrates in the PI3K/AKT, JAK/STAT, and NF-kB pathways, with other substrates 
further downstream also showing significantly less phosphorylation.  
CK2 inhibition has been particularly efficacious in overcoming resistance 
mechanisms that occur in certain cancers in response to traditional chemotherapeutic 




combination with typical standard of care chemotherapeutics was able to inhibit 
proliferation pathways, as well as CK2 mediated phosphorylation in several cancer cell 
models. Cells treated with combination of CK2 inhibitor and chemotherapeutic displayed 
markedly decreased cell viability, proliferation and increased apoptosis when compared 
to monotherapy control groups. Use of CK2 inhibition in combination with other widely 
used chemotherapeutics, needs to be further characterized to discern if in humans there 
are tolerability concerns when combining CK2 inhibitors with other potent 
chemotherapeutics such as paclitaxel, cisplatin and others, which already show 
significant tolerability and negative side effects when used alone in treatment of patients.  
This has been preliminarily addressed in several of the xenograft models discussed in the 
previous section, where an efficacious dosing regimen for combination therapy was 
found in each of the studies, with no major weight loss or toxicity effects seen. This is 
very promising, because the xenograft mice treated with both CK2 inhibitors and 
traditional chemotherapeutics often displayed greater survival, retardation of tumor 
growth, and less tumor volume/proliferation of cancer cells. Further, given the success of 
combination treatments when delivering CK2 inhibitors in nanoparticles as reviewed in 
this paper, this should be an area of further research. The targeted fashion in which 
cancer cells uptake these nanoparticles offer the potential to reach efficacy at far lower 
doses by achieving threshold tissue exposure to exert anti-cancer effect in a more 
efficient, potent fashion. Such therapies will allow for greater tolerability, more 
advantageous dosing window, and for CK2 inhibition to become a viable modality of 




Future Directions of CK2 Inhibitor Development. Although, CK2 inhibition has shown 
efficacy when used in combination with other therapeutics, the vast majority of these 
studies have explored administration of CK2 inhibitors and additional therapeutics in 
non-simultaneous dosing schedules. One future area of research for CK2 inhibitor will be 
the conjugation of CK2 inhibitors to an additional therapeutic in a prodrug, that will 
allow for multi-targeting of different components of cancerous pathways with a single 
administration. This research has begun in recent years with CX-4945 being conjugated 
to cisplatin, which showed higher cellular uptake, particularly in gastric cancer cells 
(SGC-7901 and SGC-7901/cDDP cell lines), than cisplatin alone (Chen et al., 2017). In 
addition, CX-4945/cisplatin conjugate also showed a significantly lower IC50, increased 
induction of apoptosis, when compared cisplatin, CX-4945 or equimolar mixture of 
cisplatin and CX-4945 (unconjugated), with these results also seen in a cisplatin resistant 
cell line. The prodrug also showed suppression of DNA repair mechanisms (Chen et al., 
2017). CX-4945 conjugated to cisplatin also showed much higher tumor growth 
inhibition than cisplatin alone in SGC-7901 xenograft mice (Chen et al., 2017). Similar 
results were seen in CX-4945 conjugated to cisplatin and chlorine, showing higher 
amounts of DNA damage than cisplatin single treatment (Chen et al., 2020). CX-4945 
conjugated to cisplatin and Cl as well as CX-4945 conjugated to DN604 and Cl induced 
higher levels of apoptosis in several cell lines, including in cisplatin-resistant 
A2780/cDDP cancer cells (Chen et al., 2020). The greater efficacy and ability to 
overcome resistance mechanisms will allow for more complex and thorough treatment of 





Arco, Pablo Gómez-del, Kazushige Maki, and Katia Georgopoulos. 2004. 
“Phosphorylation Controls Ikaros’s Ability To Negatively Regulate the G1-S 
Transition.” Molecular and Cellular Biology 24 (7): 2797–2807. 
https://doi.org/10.1128/MCB.24.7.2797-2807.2004. 
Arriazu, Elena, Carmen Vicente, Raffaella Pippa, Irene Peris, Elena Martínez-Balsalobre, 
Patricia García-Ramírez, Nerea Marcotegui, et al. 2020. “A New Regulatory 
Mechanism of Protein Phosphatase 2A Activity via SET in Acute Myeloid 
Leukemia.” Blood Cancer Journal 10 (1): 3. https://doi.org/10.1038/s41408-019-
0270-0. 
Benavent Acero, Fernando, Carla S. Capobianco, Juan Garona, Stéfano M. Cirigliano, 
Yasser Perera, Alejandro J. Urtreger, Silvio E. Perea, Daniel F. Alonso, and 
Hernan G. Farina. 2017. “CIGB-300, an Anti-CK2 Peptide, Inhibits 
Angiogenesis, Tumor Cell Invasion and Metastasis in Lung Cancer Models.” 
Lung Cancer, SI: Precision Medicine, 107 (May): 14–21. 
https://doi.org/10.1016/j.lungcan.2016.05.026. 
Bird, T. A., K. Schooley, S. K. Dower, H. Hagen, and G. D. Virca. 1997. “Activation of 
Nuclear Transcription Factor NF-KappaB by Interleukin-1 Is Accompanied by 
Casein Kinase II-Mediated Phosphorylation of the P65 Subunit.” The Journal of 
Biological Chemistry 272 (51): 32606–12. 
https://doi.org/10.1074/jbc.272.51.32606. 
Brown, Matthew S., Oumou T. Diallo, Michael Hu, Reza Ehsanian, Xinping Yang, 
Pattatheyil Arun, Hai Lu, et al. 2010. “CK2 Modulation of NF-KappaB, TP53, 
and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 
Oligonucleotides in Vitro or in Vivo via Sub-50-Nm Nanocapsules.” Clinical 
Cancer Research: An Official Journal of the American Association for Cancer 
Research 16 (8): 2295–2307. https://doi.org/10.1158/1078-0432.CCR-09-3200. 
Cha, Tai-Lung, Lin Qiu, Chun-Te Chen, Yong Wen, and Mien-Chie Hung. 2005. 
“Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell 
Growth.” Cancer Research 65 (6): 2287–95. https://doi.org/10.1158/0008-
5472.CAN-04-3250. 
Chen, Feihong, Xiaochao Huang, Mian Wu, Shaohua Gou, and Weiwei Hu. 2017. “A 
CK2-Targeted Pt(IV) Prodrug to Disrupt DNA Damage Response.” Cancer 
Letters 385 (January): 168–78. https://doi.org/10.1016/j.canlet.2016.10.026. 
Cho, S.-J., J.-E. Huh, J. Song, D.-K. Rhee, and S. Pyo. 2008. “Ikaros Negatively 
Regulates Inducible Nitric Oxide Synthase Expression in Macrophages: 




Molecular Life Sciences: CMLS 65 (20): 3290–3303. 
https://doi.org/10.1007/s00018-008-8332-7. 
Christian, Frank, Emma L. Smith, and Ruaidhrí J. Carmody. 2016. “The Regulation of 
NF-ΚB Subunits by Phosphorylation.” Cells 5 (1). 
https://doi.org/10.3390/cells5010012. 
Chua, Melissa M. J., Migi Lee, and Isabel Dominguez. 2017. “Cancer-Type Dependent 
Expression of CK2 Transcripts.” PLOS ONE 12 (12): e0188854. 
https://doi.org/10.1371/journal.pone.0188854. 
Cicenas, Jonas, Egle Zalyte, Amos Bairoch, and Pascale Gaudet. 2018. “Kinases and 
Cancer.” Cancers 10 (3). https://doi.org/10.3390/cancers10030063. 
Cirigliano, Stéfano M., María I. Díaz Bessone, Damián E. Berardi, Carolina Flumian, 
Elisa D. Bal de Kier Joffé, Silvio E. Perea, Hernán G. Farina, Laura B. Todaro, 
and Alejandro J. Urtreger. 2017. “The Synthetic Peptide CIGB-300 Modulates 
CK2-Dependent Signaling Pathways Affecting the Survival and Chemoresistance 
of Non-Small Cell Lung Cancer Cell Lines.” Cancer Cell International 17 (1): 42. 
https://doi.org/10.1186/s12935-017-0413-y. 
Deng, Chuangzhong, Jieping Chen, Shengjie Guo, Yanjun Wang, Qianghua Zhou, 
Zaishang Li, Xingping Yang, et al. 2017. “CX4945 Suppresses the Growth of 
Castration-Resistant Prostate Cancer Cells by Reducing AR-V7 Expression.” 
World Journal of Urology 35 (8): 1213–21. https://doi.org/10.1007/s00345-016-
1996-y. 
Di Maira, G., M. Salvi, G. Arrigoni, O. Marin, S. Sarno, F. Brustolon, L. A. Pinna, and 
M. Ruzzene. 2005. “Protein Kinase CK2 Phosphorylates and Upregulates 
Akt/PKB.” Cell Death & Differentiation 12 (6): 668–77. 
https://doi.org/10.1038/sj.cdd.4401604. 
Dixit, Deobrat, Fahim Ahmad, Ruchi Ghildiyal, Shanker Datt Joshi, and Ellora Sen. 
2016. “CK2 Inhibition Induced PDK4-AMPK Axis Regulates Metabolic 
Adaptation and Survival Responses in Glioma.” Experimental Cell Research 344 
(1): 132–42. https://doi.org/10.1016/j.yexcr.2016.03.017. 
Duncan, James S., Laszlo Gyenis, John Lenehan, Maria Bretner, Lee M. Graves, Timothy 
A. Haystead, and David W. Litchfield. 2008. “An Unbiased Evaluation of CK2 
Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and 
Identification of Novel Inhibitor Targets.” Molecular & Cellular Proteomics: 
MCP 7 (6): 1077–88. https://doi.org/10.1074/mcp.M700559-MCP200. 
Ellis, P. M., N. Coakley, R. Feld, S. Kuruvilla, and Y. C. Ung. 2015. “Use of the 




Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A 
Systematic Review.” Current Oncology (Toronto, Ont.) 22 (3): e183-215. 
https://doi.org/10.3747/co.22.2566. 
Ferrer-Font, Laura, Lucia Villamañan, Nuria Arias-Ramos, Jordi Vilardell, Maria Plana, 
Maria Ruzzene, Lorenzo A. Pinna, Emilio Itarte, Carles Arús, and Ana Paula 
Candiota. 2017. “Targeting Protein Kinase CK2: Evaluating CX-4945 Potential 
for GL261 Glioblastoma Therapy in Immunocompetent Mice.” Pharmaceuticals 
(Basel, Switzerland) 10 (1). https://doi.org/10.3390/ph10010024. 
Fritz, Gerhard, Olaf-Georg Issinger, and Birgitte Brinkmann Olsen. 2009. “Selectivity 
Analysis of Protein Kinase CK2 Inhibitors DMAT, TBB and Resorufin in 
Cisplatin-Induced Stress Responses.” International Journal of Oncology 35 (5): 
1151–57. https://doi.org/10.3892/ijo_00000431. 
Gapany, M., R. A. Faust, S. Tawfic, A. Davis, G. L. Adams, and K. Ahmed. 1995. 
“Association of Elevated Protein Kinase CK2 Activity with Aggressive Behavior 
of Squamous Cell Carcinoma of the Head and Neck.” Molecular Medicine 1 (6): 
659–66. 
Gately, L., S. A. McLachlan, A. Dowling, and J. Philip. 2017. “Life beyond a Diagnosis 
of Glioblastoma: A Systematic Review of the Literature.” Journal of Cancer 
Survivorship: Research and Practice 11 (4): 447–52. 
https://doi.org/10.1007/s11764-017-0602-7. 
Gottardo, Maria F., Carla S. Capobianco, Johanna E. Sidabra, Juan Garona, Yasser 
Perera, Silvio E. Perea, Daniel F. Alonso, and Hernan G. Farina. 2020. 
“Preclinical Efficacy of CIGB-300, an Anti-CK2 Peptide, on Breast Cancer 
Metastasic Colonization.” Scientific Reports 10 (1): 14689. 
https://doi.org/10.1038/s41598-020-71854-6. 
Gray, G. Kenneth, Braden C. McFarland, Amber L. Rowse, Sara A. Gibson, and Etty N. 
Benveniste. 2014. “Therapeutic CK2 Inhibition Attenuates Diverse Prosurvival 
Signaling Cascades and Decreases Cell Viability in Human Breast Cancer Cells.” 
Oncotarget 5 (15): 6484–96. 
Guerra, Barbara. 2006. “Protein Kinase CK2 Subunits Are Positive Regulators of AKT 
Kinase.” International Journal of Oncology 28 (3): 685–93. 
Homma, Miwako Kato, and Yoshimi Homma. 2008. “Cell Cycle and Activation of 
CK2.” Molecular and Cellular Biochemistry 316 (1): 49–55. 
https://doi.org/10.1007/s11010-008-9823-4. 
Homma, Miwako Kato, Ikuo Wada, Toshiyuki Suzuki, Junko Yamaki, Edwin G. Krebs, 




Initiation Factor 5 Potentiates Cell Cycle Progression.” Proceedings of the 
National Academy of Sciences 102 (43): 15688–93. 
https://doi.org/10.1073/pnas.0506791102. 
Huang, Mengyuan, Wenyu Yang, Jiaqing Zhu, Adrián Mariño-Enríquez, Chennianci 
Zhu, Jiaming Chen, Yuehong Wu, et al. 2020. “Coordinated Targeting of CK2 
and KIT in Gastrointestinal Stromal Tumours.” British Journal of Cancer 122 (3): 
372–81. https://doi.org/10.1038/s41416-019-0657-5. 
Jin, Chengji, Ping Song, and Ji Pang. 2019. “The CK2 Inhibitor CX4945 Reverses 
Cisplatin Resistance in the A549/DDP Human Lung Adenocarcinoma Cell Line.” 
Oncology Letters 18 (4): 3845–56. https://doi.org/10.3892/ol.2019.10696. 
Johnson, Daniel E., Rachel A. O’Keefe, and Jennifer R. Grandis. 2018. “Targeting the 
IL-6/JAK/STAT3 Signalling Axis in Cancer.” Nature Reviews Clinical Oncology 
15 (4): 234–48. https://doi.org/10.1038/nrclinonc.2018.8. 
Jung, Jung-Il, Kyeong-Yong Park, Soon Ae Kim, and Jiyeon Kim. 2018. “Synergistic 
Therapeutic Effect of Diethylstilbestrol and CX-4945 in Human Acute T-
Lymphocytic Leukemia Cells.” Biomedicine & Pharmacotherapy = Biomedecine 
& Pharmacotherapie 98 (February): 357–63. 
https://doi.org/10.1016/j.biopha.2017.12.078. 
Jung, Minkyu, Kyu Hyun Park, Hyun Myong Kim, Tae Soo Kim, Xianglan Zhang, Sun-
Mi Park, Seung-Hoon Beom, et al. 2019. “Inhibiting Casein Kinase 2 Overcomes 
Paclitaxel Resistance in Gastric Cancer.” Gastric Cancer: Official Journal of the 
International Gastric Cancer Association and the Japanese Gastric Cancer 
Association 22 (6): 1153–63. https://doi.org/10.1007/s10120-019-00971-7. 
Kaminska, Bozena, Aleksandra Ellert-Miklaszewska, Agata Oberbek, Pawel Wisniewski, 
Beata Kaza, Malgorzata Makowska, Maria Bretner, and Zygmunt Kazimierczuk. 
2009. “Efficacy and Mechanism of Anti-Tumor Action of New Potential CK2 
Inhibitors toward Glioblastoma Cells.” International Journal of Oncology 35 (5): 
1091–1100. https://doi.org/10.3892/ijo_00000424. 
Karin, Michael, and Florian R. Greten. 2005. “NF-KappaB: Linking Inflammation and 
Immunity to Cancer Development and Progression.” Nature Reviews. 
Immunology 5 (10): 749–59. https://doi.org/10.1038/nri1703. 
Karlsson-Rosenthal, Christina, and Jonathan B. A. Millar. 2006. “Cdc25: Mechanisms of 
Checkpoint Inhibition and Recovery.” Trends in Cell Biology 16 (6): 285–92. 
https://doi.org/10.1016/j.tcb.2006.04.002. 
Kato, Tomohisa, Mireille Delhase, Alexander Hoffmann, and Michael Karin. 2003. “CK2 




the UV Response.” Molecular Cell 12 (4): 829–39. https://doi.org/10.1016/s1097-
2765(03)00358-7. 
Kim, H.-R., K. Kim, K.-H. Lee, S. J. Kim, and J. Kim. 2008. “Inhibition of Casein 
Kinase 2 Enhances the Death Ligand- and Natural Kiler Cell-Induced 
Hepatocellular Carcinoma Cell Death.” Clinical and Experimental Immunology 
152 (2): 336–44. https://doi.org/10.1111/j.1365-2249.2008.03622.x. 
Kim, Jeong-Mi, Eun-Mi Noh, Hyun-Kyung Song, Yong-Ouk You, Sung Hoo Jung, Jong-
Suk Kim, Kang-Beom Kwon, Young-Rae Lee, and Hyun Jo Youn. 2018. 
“Silencing of Casein Kinase 2 Inhibits PKC‑induced Cell Invasion by Targeting 
MMP‑9 in MCF‑7 Cells.” Molecular Medicine Reports 17 (6): 8397–8402. 
https://doi.org/10.3892/mmr.2018.8885. 
Kirschner, Lawrence S. 2006. “Emerging Treatment Strategies for Adrenocortical 
Carcinoma: A New Hope.” The Journal of Clinical Endocrinology and 
Metabolism 91 (1): 14–21. https://doi.org/10.1210/jc.2005-1739. 
Krentz Gober, Madeline. 2017. “GENE EXPRESSION PROFILES REVEAL 
ALTERNATIVE TARGETS OF THERAPEUTIC INTERVENTION FOR THE 
TREATMENT OF DRUG-RESISTANT NON-SMALL CELL LUNG 
CANCERS.” Theses and Dissertations--Pharmacy, January. 
https://doi.org/10.13023/ETD.2017.309. 
Lawnicka, Hanna, Magdalena Kowalewicz-Kulbat, Paulina Sicinska, Zygmunt 
Kazimierczuk, Pawel Grieb, and Henryk Stepien. 2010. “Anti-Neoplastic Effect 
of Protein Kinase CK2 Inhibitor, 2-Dimethylamino-4,5,6,7-
Tetrabromobenzimidazole (DMAT), on Growth and Hormonal Activity of 
Human Adrenocortical Carcinoma Cell Line (H295R) in Vitro.” Cell and Tissue 
Research 340 (2): 371–79. https://doi.org/10.1007/s00441-010-0960-1. 
Lee, Hye-Rim, Seong-Jun Cho, Hye-Jin Park, Kyung-Ho Kim, Dong-Kwon Rhee, and 
Suhkneung Pyo. 2010. “The Inhibitory Effect of Acrylamide on NCAM 
Expression in Human Neuroblastoma Cells: Involvement of CK2/Ikaros Signaling 
Pathway.” Toxicology in Vitro: An International Journal Published in Association 
with BIBRA 24 (7): 1946–52. https://doi.org/10.1016/j.tiv.2010.08.004. 
Li, Dengfeng, Lei Chen, Zhen Hu, Hua Li, Jia Li, Chuankui Wei, Yixiang Huang, 
Hongming Song, and Lin Fang. 2014. “Alterations of MicroRNAs Are Associated 
with Impaired Growth of MCF-7 Breast Cancer Cells Induced by Inhibition of 
Casein Kinase 2.” International Journal of Clinical and Experimental Pathology 
7 (7): 4008–15. 
Li, Ke, Fangzheng Zhou, Yu Zhou, Sheng Zhang, Qianwen Li, Zhenyu Li, Li Liu, Gang 




Icotinib Resistance in Human Lung Adenocarcinoma Cell Lines.” International 
Journal of Molecular Medicine 44 (2): 437–46. 
https://doi.org/10.3892/ijmm.2019.4220. 
Li, Qianwen, Ke Li, Tianyang Yang, Sheng Zhang, Yu Zhou, Zhenyu Li, Jinrong Xiong, 
et al. 2017. “Association of Protein Kinase CK2 Inhibition with Cellular 
Radiosensitivity of Non-Small Cell Lung Cancer.” Scientific Reports 7 (1): 
16134. https://doi.org/10.1038/s41598-017-16012-1. 
Lian, Haiwei, Dun Li, Yun Zhou, Esther Landesman-Bollag, Guanglan Zhang, Nicole M. 
Anderson, Kevin Charles Tang, et al. 2017. “CK2 Inhibitor CX-4945 Destabilizes 
NOTCH1 and Synergizes with JQ1 against Human T-Acute Lymphoblastic 
Leukemic Cells.” Haematologica 102 (1): e17–21. 
https://doi.org/10.3324/haematol.2016.154013. 
Liu, Xiangyu, Jieyu Chen, Wei Li, Chunhua Hang, and Yuyuan Dai. 2019. “Inhibition of 
Casein Kinase II by CX-4945, But Not Yes-Associated Protein (YAP) by 
Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in 
Glioblastoma.” Translational Oncology 13 (1): 70–78. 
https://doi.org/10.1016/j.tranon.2019.09.006. 
Mandato, E., S. Manni, F. Zaffino, G. Semenzato, and F. Piazza. 2016. “Targeting CK2-
Driven Non-Oncogene Addiction in B-Cell Tumors.” Oncogene 35 (47): 6045–
52. https://doi.org/10.1038/onc.2016.86. 
Manni, Sabrina, Alessandra Brancalion, Elisa Mandato, Laura Quotti Tubi, Anna Colpo, 
Marco Pizzi, Rocco Cappellesso, et al. 2013. “Protein Kinase CK2 Inhibition 
down Modulates the NF-ΚB and STAT3 Survival Pathways, Enhances the 
Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of 
Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells.” PloS One 
8 (9): e75280. https://doi.org/10.1371/journal.pone.0075280. 
Martins, Leila R., Yasser Perera, Paulo Lúcio, Maria G. Silva, Silvio E. Perea, and João 
T. Barata. 2014. “Targeting Chronic Lymphocytic Leukemia Using CIGB-300, a 
Clinical-Stage CK2-Specific Cell-Permeable Peptide Inhibitor.” Oncotarget 5 (1): 
258–63. https://doi.org/10.18632/oncotarget.1513. 
Meng, Shuai, Yi Zhu, Jiang-Feng Li, Xiao Wang, Zhen Liang, Shi-Qi Li, Xin Xu, et al. 
2017. “Apigenin Inhibits Renal Cell Carcinoma Cell Proliferation.” Oncotarget 8 
(12): 19834–42. https://doi.org/10.18632/oncotarget.15771. 
Mostaghel, Elahe A., Bruce Montgomery, and Peter S. Nelson. 2009. “Castration-
Resistant Prostate Cancer: Targeting Androgen Metabolic Pathways in Recurrent 
Disease.” Urologic Oncology: Seminars and Original Investigations, 




Basic Urologic Research (May 2008), 27 (3): 251–57. 
https://doi.org/10.1016/j.urolonc.2009.03.016. 
Olsen, Birgitte B., Marina Bjørling-Poulsen, and Barbara Guerra. 2007. “Emodin 
Negatively Affects the Phosphoinositide 3-Kinase/AKT Signalling Pathway: A 
Study on Its Mechanism of Action.” The International Journal of Biochemistry & 
Cell Biology 39 (1): 227–37. https://doi.org/10.1016/j.biocel.2006.08.006. 
Ortega, Charina E., Yoshua Seidner, and Isabel Dominguez. 2014. “Mining CK2 in 
Cancer.” PLoS ONE 9 (12). https://doi.org/10.1371/journal.pone.0115609. 
Pagano, Mario A., Flavio Meggio, Maria Ruzzene, Mariola Andrzejewska, Zygmunt 
Kazimierczuk, and Lorenzo A. Pinna. 2004. “2-Dimethylamino-4,5,6,7-
Tetrabromo-1H-Benzimidazole: A Novel Powerful and Selective Inhibitor of 
Protein Kinase CK2.” Biochemical and Biophysical Research Communications 
321 (4): 1040–44. https://doi.org/10.1016/j.bbrc.2004.07.067. 
Pencik, Jan, Ha Thi Thanh Pham, Johannes Schmoellerl, Tahereh Javaheri, Michaela 
Schlederer, Zoran Culig, Olaf Merkel, Richard Moriggl, Florian Grebien, and 
Lukas Kenner. 2016. “JAK-STAT Signaling in Cancer: From Cytokines to Non-
Coding Genome.” Cytokine 87: 26–36. 
https://doi.org/10.1016/j.cyto.2016.06.017. 
Pepperkok, R., P. Lorenz, W. Ansorge, and W. Pyerin. 1994. “Casein Kinase II Is 
Required for Transition of G0/G1, Early G1, and G1/S Phases of the Cell Cycle.” 
Journal of Biological Chemistry 269 (9): 6986–91. 
Perea, Silvio E., Osvaldo Reyes, Idania Baladron, Yasser Perera, Hernán Farina, Jeovanis 
Gil, Arielis Rodriguez, et al. 2008. “CIGB-300, a Novel Proapoptotic Peptide 
That Impairs the CK2 Phosphorylation and Exhibits Anticancer Properties Both 
in Vitro and in Vivo.” Molecular and Cellular Biochemistry 316 (1): 163–67. 
https://doi.org/10.1007/s11010-008-9814-5. 
Perea, Silvio E., Osvaldo Reyes, Yaquelin Puchades, Osmani Mendoza, Nelson S. Vispo, 
Isis Torrens, Alicia Santos, et al. 2004. “Antitumor Effect of a Novel Proapoptotic 
Peptide That Impairs the Phosphorylation by the Protein Kinase 2 (Casein Kinase 
2).” Cancer Research 64 (19): 7127–29. https://doi.org/10.1158/0008-5472.CAN-
04-2086. 
Perera, Yasser, Alice Melão, Ailyn C. Ramón, Dania Vázquez, Daniel Ribeiro, Silvio E. 
Perea, and João T. Barata. 2020. “Clinical-Grade Peptide-Based Inhibition of 
CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 





Perera, Yasser, Seidy Pedroso, Orlando Borras-Hidalgo, Dania M. Vázquez, Jamilet 
Miranda, Adelaida Villareal, Viviana Falcón, Luis D. Cruz, Hernán G. Farinas, 
and Silvio E. Perea. 2015. “Pharmacologic Inhibition of the CK2-Mediated 
Phosphorylation of B23/NPM in Cancer Cells Selectively Modulates Genes 
Related to Protein Synthesis, Energetic Metabolism, and Ribosomal Biogenesis.” 
Molecular and Cellular Biochemistry 404 (1–2): 103–12. 
https://doi.org/10.1007/s11010-015-2370-x. 
Perera, Yasser, Neylen Del Toro, Larisa Gorovaya, Jorge Fernandez-DE-Cossio, Hernan 
G. Farina, and Silvio E. Perea. 2014. “Synergistic Interactions of the Anti-Casein 
Kinase 2 CIGB-300 Peptide and Chemotherapeutic Agents in Lung and Cervical 
Preclinical Cancer Models.” Molecular and Clinical Oncology 2 (6): 935–44. 
https://doi.org/10.3892/mco.2014.338. 
Piazza, Francesco, Sabrina Manni, and Gianpietro Semenzato. 2013. “Novel Players in 
Multiple Myeloma Pathogenesis: Role of Protein Kinases CK2 and GSK3.” 
Leukemia Research 37 (2): 221–27. https://doi.org/10.1016/j.leukres.2012.10.016. 
Pierre, Fabrice, Peter C. Chua, Sean E. O’Brien, Adam Siddiqui-Jain, Pauline Bourbon, 
Mustapha Haddach, Jerome Michaux, et al. 2011. “Pre-Clinical Characterization 
of CX-4945, a Potent and Selective Small Molecule Inhibitor of CK2 for the 
Treatment of Cancer.” Molecular and Cellular Biochemistry 356 (1–2): 37–43. 
https://doi.org/10.1007/s11010-011-0956-5. 
Prins, R. C., R. T. Burke, J. W. Tyner, B. J. Druker, M. M. Loriaux, and S. E. Spurgeon. 
2013. “CX-4945, a Selective Inhibitor of Casein Kinase-2 (CK2), Exhibits Anti-
Tumor Activity in Hematologic Malignancies Including Enhanced Activity in 
Chronic Lymphocytic Leukemia When Combined with Fludarabine and Inhibitors 
of the B-Cell Receptor Pathway.” Leukemia 27 (10): 2094–96. 
https://doi.org/10.1038/leu.2013.228. 
Pucko, Emanuela, Robert Ostrowski, and Ewa Matyja. 2019. “Novel Small Molecule 
Protein Kinase CK2 Inhibitors Exert Potent Antitumor Effects on T98G and 
SEGA Cells in Vitro.” Folia Neuropathologica 57 (3): 239–48. 
https://doi.org/10.5114/fn.2019.88452. 
Qaiser, Fatima, Janeen H. Trembley, Betsy T. Kren, Jing-Jiang Wu, A. Khaliq Naveed, 
and Khalil Ahmed. 2014. “Protein Kinase CK2 Inhibition Induces Cell Death via 
Early Impact on Mitochondrial Function.” Journal of Cellular Biochemistry 115 
(12): 2103–15. https://doi.org/10.1002/jcb.24887. 
Qaiser, Fatima, Janeen H. Trembley, Sarah Sadiq, Iqbal Muhammad, Rubina Younis, 
Shoaib Naiyar Hashmi, Badar Murtaza, Thomas S. Rector, Abdul Khaliq Naveed, 
and Khalil Ahmed. 2016. “Examination of CK2α and NF-ΚB P65 Expression in 




and Cellular Biochemistry 420 (1–2): 43–51. https://doi.org/10.1007/s11010-016-
2765-3. 
Revathidevi, Sundaramoorthy, and Arasambattu Kannan Munirajan. 2019. “Akt in 
Cancer: Mediator and More.” Seminars in Cancer Biology, PI3K/AKT signaling 
in human cancer &New insights in melanoma biology: running fast towards 
precision medicine, 59 (December): 80–91. 
https://doi.org/10.1016/j.semcancer.2019.06.002. 
Richter, Anna, Catrin Roolf, Mohamed Hamed, Yvonne Saara Gladbach, Sina Sender, 
Christoph Konkolefski, Gudrun Knübel, et al. 2019. “Combined Casein Kinase II 
Inhibition and Epigenetic Modulation in Acute B-Lymphoblastic Leukemia.” 
BMC Cancer 19 (1): 202. https://doi.org/10.1186/s12885-019-5411-0. 
Richter, Anna, Sina Sender, Annemarie Lenz, Rico Schwarz, Burkhard Hinz, Gudrun 
Knuebel, Anett Sekora, Hugo Murua Escobar, Christian Junghanss, and Catrin 
Roolf. 2020. “Influence of Casein Kinase II Inhibitor CX-4945 on BCL6-
Mediated Apoptotic Signaling in B-ALL in Vitro and in Vivo.” BMC Cancer 20 
(1): 184. https://doi.org/10.1186/s12885-020-6650-9. 
Sarno, Stefania, Erika de Moliner, Maria Ruzzene, Mario A Pagano, Roberto Battistutta, 
Jenny Bain, Doriano Fabbro, et al. 2003. “Biochemical and Three-Dimensional-
Structural Study of the Specific Inhibition of Protein Kinase CK2 by [5-Oxo-5,6-
Dihydroindolo-(1,2-a)Quinazolin-7-Yl]Acetic Acid (IQA).” Biochemical Journal 
374 (Pt 3): 639–46. https://doi.org/10.1042/BJ20030674. 
Sarno, Stefania, Maria Ruzzene, Pietrogiulio Frascella, Mario A. Pagano, Flavio Meggio, 
Alfonso Zambon, Marco Mazzorana, Giovanni Di Maira, Vittorio Lucchini, and 
Lorenzo A. Pinna. 2005. “Development and Exploitation of CK2 Inhibitors.” 
Molecular and Cellular Biochemistry 274 (1): 69–76. 
https://doi.org/10.1007/s11010-005-3079-z. 
Sass, Gabriele, Nina Klinger, Hüseyin Sirma, Said Hashemolhosseini, Claus Hellerbrand, 
Daniel Neureiter, Henning Wege, Matthias Ocker, and Gisa Tiegs. 2011. 
“Inhibition of Experimental HCC Growth in Mice by Use of the Kinase Inhibitor 
DMAT.” International Journal of Oncology 39 (2): 433–42. 
https://doi.org/10.3892/ijo.2011.1037. 
Schneider, Carolin C., Claudia Götz, Andrea Hessenauer, Jürgen Günther, Sabine 
Kartarius, and Mathias Montenarh. 2011. “Down-Regulation of CK2 Activity 
Results in a Decrease in the Level of Cdc25C Phosphatase in Different Prostate 
Cancer Cell Lines.” Molecular and Cellular Biochemistry 356 (1–2): 177–84. 
https://doi.org/10.1007/s11010-011-0946-7. 




“P53 Is Dispensable for the Induction of Apoptosis after Inhibition of Protein 
Kinase CK2.” The Prostate 70 (2): 126–34. https://doi.org/10.1002/pros.21044. 
Seeber, S., O. G. Issinger, T. Holm, L. P. Kristensen, and B. Guerra. 2005. “Validation of 
Protein Kinase CK2 as Oncological Target.” Apoptosis 10 (4): 875–85. 
https://doi.org/10.1007/s10495-005-0380-y. 
Solares, Ana M, Agueda Santana, Idania Baladrón, Carmen Valenzuela, Carlos A 
González, Alina Díaz, Dagnelia Castillo, et al. 2009. “Safety and Preliminary 
Efficacy Data of a Novel Casein Kinase 2 (CK2) Peptide Inhibitor Administered 
Intralesionally at Four Dose Levels in Patients with Cervical Malignancies.” BMC 
Cancer 9 (May): 146. https://doi.org/10.1186/1471-2407-9-146. 
Spiro, S. G., R. M. Rudd, R. L. Souhami, J. Brown, D. J. Fairlamb, N. H. Gower, L. 
Maslove, et al. 2004. “Chemotherapy versus Supportive Care in Advanced Non-
Small Cell Lung Cancer: Improved Survival without Detriment to Quality of 
Life.” Thorax 59 (10): 828–36. https://doi.org/10.1136/thx.2003.020164. 
Stupp, Roger, Warren P. Mason, Martin J. van den Bent, Michael Weller, Barbara Fisher, 
Martin J. B. Taphoorn, Karl Belanger, et al. 2005. “Radiotherapy plus 
Concomitant and Adjuvant Temozolomide for Glioblastoma.” The New England 
Journal of Medicine 352 (10): 987–96. https://doi.org/10.1056/NEJMoa043330. 
Taniguchi, Koji, and Michael Karin. 2018. “NF-ΚB, Inflammation, Immunity and 
Cancer: Coming of Age.” Nature Reviews Immunology 18 (5): 309–24. 
https://doi.org/10.1038/nri.2017.142. 
Tarver, Will L., and David A. Haggstrom. 2019. “The Use of Cancer-Specific Patient-
Centered Technologies Among Underserved Populations in the United States: 
Systematic Review.” Journal of Medical Internet Research 21 (4): e10256. 
https://doi.org/10.2196/10256. 
Trembley, Janeen H., Betsy T. Kren, Md. Joynal Abedin, Rachel I. Vogel, Claire M. 
Cannon, Gretchen M. Unger, and Khalil Ahmed. 2017. “CK2 Molecular 
Targeting—Tumor Cell-Specific Delivery of RNAi in Various Models of 
Cancer.” Pharmaceuticals 10 (1). https://doi.org/10.3390/ph10010025. 
Trembley, Janeen H., Gretchen M. Unger, Omar Cespedes Gomez, J. Abedin, Vicci L. 
Korman, Rachel I. Vogel, Gloria Niehans, Betsy T. Kren, and Khalil Ahmed. 
2014. “Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate 
Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.” Molecular 
and Cellular Pharmacology 6 (2): 15–25. 
Trembley, Janeen H., Gretchen M. Unger, Vicci L. Korman, Diane K. Tobolt, Zygmunt 




“Nanoencapsulated Anti-CK2 Small Molecule Drug or SiRNA Specifically 
Targets Malignant Cancer but Not Benign Cells.” Cancer Letters 315 (1): 48–58. 
https://doi.org/10.1016/j.canlet.2011.10.007. 
Wang, D., and A. S. Baldwin. 1998. “Activation of Nuclear Factor-KappaB-Dependent 
Transcription by Tumor Necrosis Factor-Α Is Mediated through Phosphorylation 
of RelA/P65 on Serine 529.” The Journal of Biological Chemistry 273 (45): 
29411–16. https://doi.org/10.1074/jbc.273.45.29411. 
Wang, D., S. D. Westerheide, J. L. Hanson, and A. S. Baldwin. 2000. “Tumor Necrosis 
Factor Α-Induced Phosphorylation of RelA/P65 on Ser529 Is Controlled by 
Casein Kinase II.” The Journal of Biological Chemistry 275 (42): 32592–97. 
https://doi.org/10.1074/jbc.M001358200. 
Wang, Haiyun, Qi Lv, Yue Xu, Zhaoqing Cai, Jie Zheng, Xiaojie Cheng, Yao Dai, Pasi 
A. Jänne, Chiara Ambrogio, and Jens Köhler. 2019. “An Integrative 
Pharmacogenomics Analysis Identifies Therapeutic Targets in KRAS-Mutant 
Lung Cancer.” EBioMedicine 49 (October): 106–17. 
https://doi.org/10.1016/j.ebiom.2019.10.012. 
Wang, Huamin, Alan Davis, Shihui Yu, and Khalil Ahmed. 2001. “Response of Cancer 
Cells to Molecular Interruption of the CK2 Signal.” Molecular and Cellular 
Biochemistry 227 (1): 167–74. https://doi.org/10.1023/A:1013112908734. 
Wu, Tong, Xuan Wu, Hong-Yang Wang, and Lei Chen. 2019. “Immune Contexture 
Defined by Single Cell Technology for Prognosis Prediction and Immunotherapy 
Guidance in Cancer.” Cancer Communications (London, England) 39 (1): 21. 
https://doi.org/10.1186/s40880-019-0365-9. 
Yang, Bo, Jinhong Yao, Bai Li, Guoguang Shao, and Yongsheng Cui. 2017. “Inhibition 
of Protein Kinase CK2 Sensitizes Non-Small Cell Lung Cancer Cells to Cisplatin 
via Upregulation of PML.” Molecular and Cellular Biochemistry 436 (1): 87–97. 
https://doi.org/10.1007/s11010-017-3081-2. 
Yde, C. W., B. B. Olsen, D. Meek, N. Watanabe, and B. Guerra. 2008. “The Regulatory 
β-Subunit of Protein Kinase CK2 Regulates Cell-Cycle Progression at the Onset 
of Mitosis.” Oncogene 27 (37): 4986–97. https://doi.org/10.1038/onc.2008.146. 
Yde, Christina Westmose, Thomas Frogne, Anne E. Lykkesfeldt, Iduna Fichtner, Olaf-
Georg Issinger, and Jan Stenvang. 2007. “Induction of Cell Death in Antiestrogen 
Resistant Human Breast Cancer Cells by the Protein Kinase CK2 Inhibitor 
DMAT.” Cancer Letters 256 (2): 229–37. 
https://doi.org/10.1016/j.canlet.2007.06.010. 




Rodriguez, Katherine Marcelain, Ricardo Armisen, Andrew F. G. Quest, and Julio 
C. Tapia. 2011. “Protein Kinase CK2 Promotes Cancer Cell Viability via Up-
Regulation of Cyclooxygenase-2 Expression and Enhanced Prostaglandin E2 
Production.” Journal of Cellular Biochemistry 112 (11): 3167–75. 
https://doi.org/10.1002/jcb.23247. 
Zakharia, Kais, Katsuyuki Miyabe, Yu Wang, Dehai Wu, Catherine D. Moser, Mitesh J. 
Borad, and Lewis R. Roberts. 2019. “Preclinical In Vitro and In Vivo Evidence of 
an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in 
Cholangiocarcinoma.” Translational Oncology 12 (1): 143–53. 
https://doi.org/10.1016/j.tranon.2018.09.005. 
Zaman, Mohammad S., Adam J. Johnson, Gayani Petersingham, Gerald W. Muench, 
Qihan Dong, and Ming J. Wu. 2019. “Protein Kinase CK2 Is Involved in Zinc 
Homeostasis in Breast and Prostate Cancer Cells.” Biometals: An International 
Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine 32 (6): 
861–73. https://doi.org/10.1007/s10534-019-00218-z. 
Zeng, Xiang, Tsukasa Baba, Junzo Hamanishi, Noriomi Matsumura, Budiman Kharma, 
Yuka Mise, Kaoru Abiko, et al. 2019. “Phosphorylation of STAT1 Serine 727 
Enhances Platinum Resistance in Uterine Serous Carcinoma.” International 
Journal of Cancer 145 (6): 1635–47. https://doi.org/10.1002/ijc.32501. 
Zhao, Tiesuo, Huijie Jia, Lifei Li, Guoliang Zhang, Min Zhao, Qian Cheng, Junnian 
Zheng, and Di Li. 2013. “Inhibition of CK2 Enhances UV-Triggered Apoptotic 
Cell Death in Lung Cancer Cell Lines.” Oncology Reports 30 (1): 377–84. 
https://doi.org/10.3892/or.2013.2407. 
Zheng, Ying, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo 
Kim, Markus Bredel, and Etty N. Benveniste. 2013. “Targeting Protein Kinase 
CK2 Suppresses Pro-Survival Signaling Pathways and Growth of Glioblastoma.” 
Clinical Cancer Research : An Official Journal of the American Association for 
Cancer Research 19 (23): 6484–94. https://doi.org/10.1158/1078-0432.CCR-13-
0265. 
Zhou, Y., K. Li, S. Zhang, Q. Li, Z. Li, F. Zhou, X. Dong, L. Liu, G. Wu, and R. Meng. 
2015. “Quinalizarin, a Specific CK2 Inhibitor, Reduces Cell Viability and 
Suppresses Migration and Accelerates Apoptosis in Different Human Lung 
Cancer Cell Lines.” Indian Journal of Cancer 52 Suppl 2 (December): e119-124. 
https://doi.org/10.4103/0019-509X.172508. 
Zwicker, Felix, Henrik Hauswald, Klaus-Josef Weber, JÜrgen Debus, and Peter E. 
Huber. 2021. “In Vivo Evaluation of Combined CK2 Inhibition and Irradiation in 













         
 
73 
 
74 
